Loading...
Header Logo
Keywords
Last Name
Institution

ROBERT C BAST JR

TitleProfessor
InstitutionMD Anderson
DepartmentExperimental Therapeutics
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, Adamoski D, Pasculli B, Taguchi A, Chen Y, Fernandez AF, Valledor L, Van Roosbroeck K, Chang S, Shah M, Kinnebrew G, Han L, Atlasi Y, Cheung LH, Huang GY, Monroig P, Ramirez MS, Catela Ivkovic T, Van L, Ling H, Gafà R, Kapitanovic S, Lanza G, Bankson JA, Huang P, Lai SY, Bast RC, Rosenblum MG, Radovich M, Ivan M, Bartholomeusz G, Liang H, Fraga MF, Widger WR, Hanash S, Berindan-Neagoe I, Lopez-Berestein G, Ambrosio ALB, Gomes Dias SM, Calin GA. Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. Mol Cell. 2016 Feb 18; 61(4):520-534. PMID: 26853146.
      View in: PubMed
    2. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC, Bennett JM, Benz EJ, Berliner N, Bertino J, Bhatia R, Bhatia S, Bhojwani D, Blanke CD, Bloomfield CD, Bosserman L, Broxmeyer HE, Byrd JC, Cabanillas F, Canellos GP, Chabner BA, Chanan-Khan A, Cheson B, Clarkson B, Cohn SL, Colon-Otero G, Cortes J, Coutre S, Cristofanilli M, Curran WJ, Daley GQ, DeAngelo DJ, Deeg HJ, Einhorn LH, Erba HP, Esteva FJ, Estey E, Fidler IJ, Foran J, Forman S, Freireich E, Fuchs C, George JN, Gertz MA, Giralt S, Golomb H, Greenberg P, Gutterman J, Handin RI, Hellman S, Hoff PM, Hoffman R, Hong WK, Horowitz M, Hortobagyi GN, Hudis C, Issa JP, Johnson BE, Kantoff PW, Kaushansky K, Khayat D, Khuri FR, Kipps TJ, Kripke M, Kyle RA, Larson RA, Lawrence TS, Levine R, Link MP, Lippman SM, Lonial S, Lyman GH, Markman M, Mendelsohn J, Meropol NJ, Messinger Y, Mulvey TM, O'Brien S, Perez-Soler R, Pollock R, Prchal J, Press O, Radich J, Rai K, Rosenberg SA, Rowe JM, Rugo H, Runowicz CD, Sandmaier BM, Saven A, Schafer AI, Schiffer C, Sekeres MA, Silver RT, Siu LL, Steensma DP, Stewart FM, Stock W, Stone R, Storb R, Strong LC, Tallman MS, Thompson M, Ueno NT, Van Etten RA, Vose JM, Wiernik PH, Winer EP, Younes A, Zelenetz AD, LeMaistre CA. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. PMID: 26211600.
      View in: PubMed
    3. Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, Hicks DG, Hill EG, Liu MC, Lucas W, Mayer IA, Mennel RG, Symmans WF, Hayes DF, Harris LN. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2015 Aug 20; 33(24):2695-704. PMID: 26195705.
      View in: PubMed
    4. Shadfan BH, Simmons AR, Simmons GW, Ho A, Wong J, Lu KH, Bast RC, McDevitt JT. A multiplexable, microfluidic platform for the rapid quantitation of a biomarker panel for early ovarian cancer detection at the point-of-care. Cancer Prev Res (Phila). 2015 Jan; 8(1):37-48. PMID: 25388014.
      View in: PubMed
    5. Deniger DC, Maiti SN, Mi T, Switzer KC, Ramachandran V, Hurton LV, Ang S, Olivares S, Rabinovich BA, Huls MH, Lee DA, Bast RC, Champlin RE, Cooper LJ. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies. Clin Cancer Res. 2014 Nov 15; 20(22):5708-19. PMID: 24833662.
      View in: PubMed
    6. Holman LL, Lu KH, Bast RC, Hernandez MA, Bodurka DC, Skates S, Sun CC. Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. Am J Obstet Gynecol. 2014 Mar; 210(3):257.e1-6. PMID: 24246524.
      View in: PubMed
    7. Lyu T, Jia N, Wang J, Yan X, Yu Y, Lu Z, Bast RC, Hua K, Feng W. Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics. 2013 Dec; 8(12):1330-46. PMID: 24135786.
      View in: PubMed
    8. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, Moore R, Granai C, Harris S, Newland W, Adeyinka O, Geffen J, Deavers MT, Sun CC, Horick N, Fritsche H, Bast RC. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013 Oct 01; 119(19):3454-61. PMID: 23983047.
      View in: PubMed
    9. Zhang Z, Zhu Y, Lai Y, Wu X, Feng Z, Yu Y, Bast RC, Wan X, Xi X, Feng Y. Follicle-stimulating hormone inhibits apoptosis in ovarian cancer cells by regulating the OCT4 stem cell signaling pathway. Int J Oncol. 2013 Oct; 43(4):1194-204. PMID: 23921511.
      View in: PubMed
    10. Chen X, Zhang J, Cheng W, Chang DY, Huang J, Wang X, Jia L, Rosen DG, Zhang W, Yang D, Gershenson DM, Sood AK, Bast RC, Liu J. CA-125 level as a prognostic indicator in type I and type II epithelial ovarian cancer. Int J Gynecol Cancer. 2013 Jun; 23(5):815-22. PMID: 23669443.
      View in: PubMed
    11. Simmons AR, Baggerly K, Bast RC. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park). 2013 Jun; 27(6):548-56. PMID: 23909069.
      View in: PubMed
    12. Tao X, Zhao N, Jin H, Zhang Z, Liu Y, Wu J, Bast RC, Yu Y, Feng Y. FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3. Endocr Relat Cancer. 2013 Jun; 20(3):415-29. PMID: 23580589.
      View in: PubMed
    13. Romero I, Sun CC, Wong KK, Bast RC, Gershenson DM. Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol. 2013 Sep; 130(3):660-6. PMID: 23707670.
      View in: PubMed
    14. Lu Z, Bast RC. The tumor suppressor gene ARHI (DIRAS3) inhibits ovarian cancer cell migration through multiple mechanisms. Cell Adh Migr. 2013 Mar-Apr; 7(2):232-6. PMID: 23357870.
      View in: PubMed
    15. Diamandis EP, Bast RC, Gold P, Chu TM, Magnani JL. Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9. Clin Chem. 2013 Jan; 59(1):22-31. PMID: 23204222.
      View in: PubMed
    16. Diamandis EP, Bast RC, Lopez-Otín C. Conquering cancer in our lifetime: new diagnostic and therapeutic trends. Clin Chem. 2013 Jan; 59(1):1-3. PMID: 23204223.
      View in: PubMed
    17. Fu S, Li Y, Huang J, Liu T, Hong Z, Chen A, Bast RC, Kavanagh JJ, Gershenson DM, Sood AK, Hu W. Aurora kinase inhibitor VE 465 synergistically enhances cytotoxicity of carboplatin in ovarian cancer cells through induction of apoptosis and downregulation of histone 3. Cancer Biol Ther. 2012 Sep; 13(11):1034-41. PMID: 22895067.
      View in: PubMed
    18. Jia L, Zhang S, Ye Y, Li X, Mercado-Uribe I, Bast RC, Liu J. Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Lett. 2012 Dec 30; 326(2):176-82. PMID: 22902993.
      View in: PubMed
    19. Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. PLoS One. 2012; 7(7):e41170. PMID: 22829924.
      View in: PubMed
    20. Xu J, Shetty PB, Feng W, Chenault C, Bast RC, Issa JP, Hilsenbeck SG, Yu Y. Methylation of HIN-1, RASSF1A, RIL and CDH13 in breast cancer is associated with clinical characteristics, but only RASSF1A methylation is associated with outcome. BMC Cancer. 2012 Jun 13; 12:243. PMID: 22695491.
      View in: PubMed
    21. Bast RC, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer. 2012 May; 22 Suppl 1:S5-8. PMID: 22543921.
      View in: PubMed
    22. Raamanathan A, Simmons GW, Christodoulides N, Floriano PN, Furmaga WB, Redding SW, Lu KH, Bast RC, McDevitt JT. Programmable bio-nano-chip systems for serum CA125 quantification: toward ovarian cancer diagnostics at the point-of-care. Cancer Prev Res (Phila). 2012 May; 5(5):706-16. PMID: 22490510.
      View in: PubMed
    23. Fu S, Hennessy BT, Ng CS, Ju Z, Coombes KR, Wolf JK, Sood AK, Levenback CF, Coleman RL, Kavanagh JJ, Gershenson DM, Markman M, Dice K, Howard A, Li J, Li Y, Stemke-Hale K, Dyer M, Atkinson E, Jackson E, Kundra V, Kurzrock R, Bast RC, Mills GB. Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):47-53. PMID: 22487539.
      View in: PubMed
    24. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Bánhegyi G, Bartholomew CR, Bassham DC, Bast RC, Batoko H, Bay BH, Beau I, Béchet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahová M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen X, Chen X, Chen YG, Chen Y, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M, Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronjé MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Díaz-Araya G, Díaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farré JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fésüs L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544. PMID: 22966490.
      View in: PubMed
    25. Romero I, Bast RC. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012 Apr; 153(4):1593-602. PMID: 22416079.
      View in: PubMed
    26. Ahmed AA, Becker CM, Bast RC. The origin of ovarian cancer. BJOG. 2012 Jan; 119(2):134-6. PMID: 22168761.
      View in: PubMed
    27. Auzenne EJ, Klostergaard J, Mandal PK, Liao WS, Lu Z, Gao F, Bast RC, Robertson FM, McMurray JS. A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. J Exp Ther Oncol. 2012; 10(2):155-62. PMID: 23350355.
      View in: PubMed
    28. Bast RC, Mills GB. Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer. Cancer Discov. 2012 Jan; 2(1):16-8. PMID: 22585163.
      View in: PubMed
    29. Moore RG, Miller MC, Eklund EE, Lu KH, Bast RC, Lambert-Messerlian G. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol. 2012 Apr; 206(4):349.e1-7. PMID: 22301440.
      View in: PubMed
    30. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert-Messerlian G, Bast RC. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. Am J Obstet Gynecol. 2012 Apr; 206(4):351.e1-8. PMID: 22284961.
      View in: PubMed
    31. Bast RC. Molecular approaches to personalizing management of ovarian cancer. Ann Oncol. 2011 Dec; 22 Suppl 8:viii5-viii15. PMID: 22180401.
      View in: PubMed
    32. Russell P, Hennessy BT, Li J, Carey MS, Bast RC, Freeman T, Venkitaraman AR. Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest. Oncogene. 2012 May 10; 31(19):2450-60. PMID: 22056875.
      View in: PubMed
    33. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012 May 15; 118(10):2603-14. PMID: 22370716.
      View in: PubMed
    34. Chen MY, Liao WS, Lu Z, Bornmann WG, Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA, Bast RC. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer. 2011 Oct 01; 117(19):4424-38. PMID: 21491416.
      View in: PubMed
    35. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25. PMID: 21941283.
      View in: PubMed
    36. Su JL, Cheng X, Yamaguchi H, Chang YW, Hou CF, Lee DF, Ko HW, Hua KT, Wang YN, Hsiao M, Chen PB, Hsu JM, Bast RC, Hortobagyi GN, Hung MC. FOXO3a-Dependent Mechanism of E1A-Induced Chemosensitization. Cancer Res. 2011 Nov 01; 71(21):6878-87. PMID: 21911455.
      View in: PubMed
    37. Le XF, Bast RC. Src family kinases and paclitaxel sensitivity. Cancer Biol Ther. 2011 Aug 15; 12(4):260-9. PMID: 21646863.
      View in: PubMed
    38. Le XF, Mao W, He G, Claret FX, Xia W, Ahmed AA, Hung MC, Siddik ZH, Bast RC. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells. J Natl Cancer Inst. 2011 Sep 21; 103(18):1403-22. PMID: 21813412.
      View in: PubMed
    39. Ahmed AA, Wang X, Lu Z, Goldsmith J, Le XF, Grandjean G, Bartholomeusz G, Broom B, Bast RC. Modulating microtubule stability enhances the cytotoxic response of cancer cells to Paclitaxel. Cancer Res. 2011 Sep 01; 71(17):5806-17. PMID: 21775522.
      View in: PubMed
    40. Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer. 2012 Jan 01; 118(1):91-100. PMID: 21717433.
      View in: PubMed
    41. Clarke CH, Yip C, Badgwell D, Fung ET, Coombes KR, Zhang Z, Lu KH, Bast RC. Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol Oncol. 2011 Sep; 122(3):548-53. PMID: 21708402.
      View in: PubMed
    42. Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, Bao JJ, Das P, Andreeff M, Chen W, Yu Y, Ahmed AA, S-L Liao W, Bast RC. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene. 2012 Jan 05; 31(1):68-79. PMID: 21643014.
      View in: PubMed
    43. Bast RC, Spriggs DR. More than a biomarker: CA125 may contribute to ovarian cancer pathogenesis. Gynecol Oncol. 2011 Jun 01; 121(3):429-30. PMID: 21601106.
      View in: PubMed
    44. Mandal PK, Gao F, Lu Z, Ren Z, Ramesh R, Birtwistle JS, Kaluarachchi KK, Chen X, Bast RC, Liao WS, McMurray JS. Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3. J Med Chem. 2011 May 26; 54(10):3549-63. PMID: 21486047.
      View in: PubMed
    45. Diao L, Clarke CH, Coombes KR, Hamilton SR, Roth J, Mao L, Czerniak B, Baggerly KA, Morris JS, Fung ET, Bast RC. Reproducibility of SELDI Spectra Across Time and Laboratories. Cancer Inform. 2011 Mar 14; 10:45-64. PMID: 21552492.
      View in: PubMed
    46. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, Lokshin AE, McIntosh MW, Skates SJ, Vitonis A, Zhang Z, Ward DC, Symanowski JT, Lomakin A, Fung ET, Sluss PM, Scholler N, Lu KH, Marrangoni AM, Patriotis C, Srivastava S, Buys SS, Berg CD. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011 Mar; 4(3):375-83. PMID: 21372037.
      View in: PubMed
    47. Cramer DW, Bast RC, Berg CD, Diamandis EP, Godwin AK, Hartge P, Lokshin AE, Lu KH, McIntosh MW, Mor G, Patriotis C, Pinsky PF, Thornquist MD, Scholler N, Skates SJ, Sluss PM, Srivastava S, Ward DC, Zhang Z, Zhu CS, Urban N. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011 Mar; 4(3):365-74. PMID: 21372036.
      View in: PubMed
    48. Ahmed AA, Goldsmith J, Fokt I, Le XF, Krzysko KA, Lesyng B, Bast RC, Priebe W. A genistein derivative, ITB-301, induces microtubule depolymerization and mitotic arrest in multidrug-resistant ovarian cancer. Cancer Chemother Pharmacol. 2011 Oct; 68(4):1033-44. PMID: 21340606.
      View in: PubMed
    49. Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, Lu Z, Bast RC, Feng Y, Yu Y. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer. 2011 Jan 19; 11:22. PMID: 21244707.
      View in: PubMed
    50. Hennessey VG, Rosner GL, Bast RC, Chen MY. A Bayesian approach to dose-response assessment and synergy and its application to in vitro dose-response studies. Biometrics. 2010 Dec; 66(4):1275-83. PMID: 20337630.
      View in: PubMed
    51. Fu S, Hu W, Iyer R, Kavanagh JJ, Coleman RL, Levenback CF, Sood AK, Wolf JK, Gershenson DM, Markman M, Hennessy BT, Kurzrock R, Bast RC. Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Cancer. 2011 Apr 15; 117(8):1661-9. PMID: 21472713.
      View in: PubMed
    52. Le XF, Mao W, Lu Z, Carter BZ, Bast RC. Dasatinib induces autophagic cell death in human ovarian cancer. Cancer. 2010 Nov 01; 116(21):4980-90. PMID: 20629079.
      View in: PubMed
    53. Landen CN, Goodman B, Katre AA, Steg AD, Nick AM, Stone RL, Miller LD, Mejia PV, Jennings NB, Gershenson DM, Bast RC, Coleman RL, Lopez-Berestein G, Sood AK. Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther. 2010 Dec; 9(12):3186-99. PMID: 20889728.
      View in: PubMed
    54. Bast RC, Markman M. Chemotherapy: A new standard combination for recurrent ovarian cancer? Nat Rev Clin Oncol. 2010 Oct; 7(10):559-60. PMID: 20877420.
      View in: PubMed
    55. Ahmed AA, Lu Z, Jennings NB, Etemadmoghadam D, Capalbo L, Jacamo RO, Barbosa-Morais N, Le XF, Vivas-Mejia P, Lopez-Berestein G, Grandjean G, Bartholomeusz G, Liao W, Andreeff M, Bowtell D, Glover DM, Sood AK, Bast RC. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer. Cancer Cell. 2010 Aug 09; 18(2):109-21. PMID: 20708153.
      View in: PubMed
    56. Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC, Yu Y. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer. 2010 Jul 20; 10:378. PMID: 20642860.
      View in: PubMed
    57. Yang H, Lu X, Qian J, Xu F, Hu Y, Yu Y, Bast RC, Li J. Imprinted tumor suppressor gene ARHI induces apoptosis correlated with changes in DNA methylation in pancreatic cancer cells. Mol Med Rep. 2010 Jul-Aug; 3(4):581-7. PMID: 21472283.
      View in: PubMed
    58. Bast RC. CA 125 and the detection of recurrent ovarian cancer: a reasonably accurate biomarker for a difficult disease. Cancer. 2010 Jun 15; 116(12):2850-3. PMID: 20564390.
      View in: PubMed
    59. Bast RC, Mills GB. Personalizing therapy for ovarian cancer: BRCAness and beyond. J Clin Oncol. 2010 Aug 01; 28(22):3545-8. PMID: 20547987.
      View in: PubMed
    60. Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast RC, Zhang Z, Nicoletto MO. Combined use of biomarkers for detection of ovarian cancer in high-risk women. Tumour Biol. 2010 Jun; 31(3):209-15. PMID: 20393825.
      View in: PubMed
    61. Liu G, Yang G, Chang B, Mercado-Uribe I, Huang M, Zheng J, Bast RC, Lin SH, Liu J. Stanniocalcin 1 and ovarian tumorigenesis. J Natl Cancer Inst. 2010 Jun 02; 102(11):812-27. PMID: 20484106.
      View in: PubMed
    62. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010 Sep; 203(3):228.e1-6. PMID: 20471625.
      View in: PubMed
    63. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC, Lokshin AE. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010 May 01; 28(13):2159-66. PMID: 20368574.
      View in: PubMed
    64. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC, Lokshin A. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010 Jun; 117(3):440-5. PMID: 20334903.
      View in: PubMed
    65. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast RC. Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol. 2010 Mar 11; 3:9. PMID: 20222977.
      View in: PubMed
    66. Le XF, Merchant O, Bast RC, Calin GA. The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. Cancer Microenviron. 2010 Feb 23; 3(1):137-47. PMID: 21209780.
      View in: PubMed
    67. Zheng J, Mercado-Uribe I, Rosen DG, Chang B, Liu P, Yang G, Malpica A, Naora H, Auersperg N, Mills GB, Bast RC, Liu J. Induction of papillary carcinoma in human ovarian surface epithelial cells using combined genetic elements and peritoneal microenvironment. Cell Cycle. 2010 Jan 01; 9(1):140-6. PMID: 20016289.
      View in: PubMed
    68. Bast RC. Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs. Cancer Biomark. 2010-2011; 8(4-5):161-6. PMID: 22045350.
      View in: PubMed
    69. Huang S, Chang IS, Lin W, Ye W, Luo RZ, Lu Z, Lu Y, Zhang K, Liao WS, Tao T, Bast RC, Chen X, Yu Y. ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Biosci Rep. 2009 Dec 15; 30(3):159-68. PMID: 19435463.
      View in: PubMed
    70. Moore RG, MacLaughlan S, Bast RC. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol. 2010 Feb; 116(2):240-5. PMID: 19879639.
      View in: PubMed
    71. Samanta AK, Huang HJ, Le XF, Mao W, Lu KH, Bast RC, Liao WS. MEKK3 expression correlates with nuclear factor kappa B activity and with expression of antiapoptotic genes in serous ovarian carcinoma. Cancer. 2009 Sep 01; 115(17):3897-908. PMID: 19517469.
      View in: PubMed
    72. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, Chen CT, Trinh BQ, Lu Z, Ueno NT, Wolf JK, Bast RC, Hung MC. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther. 2009 Aug; 8(8):2375-82. PMID: 19671744.
      View in: PubMed
    73. Kurzrock R, Pilat S, Bartolazzi M, Sanders D, Van Wart Hood J, Tucker SD, Webster K, Mallamaci MA, Strand S, Babcock E, Bast RC. Project Zero Delay: a process for accelerating the activation of cancer clinical trials. J Clin Oncol. 2009 Sep 10; 27(26):4433-40. PMID: 19652061.
      View in: PubMed
    74. Bast RC, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009 Jun; 9(6):415-28. PMID: 19461667.
      View in: PubMed
    75. Cheon DJ, Wang Y, Deng JM, Lu Z, Xiao L, Chen CM, Bast RC, Behringer RR. CA125/MUC16 is dispensable for mouse development and reproduction. PLoS One. 2009; 4(3):e4675. PMID: 19262696.
      View in: PubMed
    76. Lu Z, Bast RC. Tumor suppressor genes. Cancer Treat Res. 2009; 149:109-29. PMID: 19763433.
      View in: PubMed
    77. Le XF, Mao W, Lu C, Thornton A, Heymach JV, Sood AK, Bast RC. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle. 2008 Dec; 7(23):3747-58. PMID: 19029832.
      View in: PubMed
    78. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brünner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih IeM, Sibley P, Sölétormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008 Dec; 54(12):e11-79. PMID: 19042984.
      View in: PubMed
    79. Lu Z, Luo RZ, Lu Y, Zhang X, Yu Q, Khare S, Kondo S, Kondo Y, Yu Y, Mills GB, Liao WS, Bast RC. The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. J Clin Invest. 2008 Dec; 118(12):3917-29. PMID: 19033662.
      View in: PubMed
    80. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC, Kruk PA. Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol. 2009 Jan; 112(1):60-7. PMID: 19007973.
      View in: PubMed
    81. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009 Jan; 112(1):40-6. PMID: 18851871.
      View in: PubMed
    82. Wei Y, Xia W, Zhang Z, Liu J, Wang H, Adsay NV, Albarracin C, Yu D, Abbruzzese JL, Mills GB, Bast RC, Hortobagyi GN, Hung MC. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog. 2008 Sep; 47(9):701-6. PMID: 18176935.
      View in: PubMed
    83. Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation. 2008 Dec; 76(10):1081-92. PMID: 18637025.
      View in: PubMed
    84. Das PM, Bast RC. Early detection of ovarian cancer. Biomark Med. 2008 Jun; 2(3):291-303. PMID: 20477415.
      View in: PubMed
    85. Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, Granai CO, Bast RC, Lu K. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008 Aug; 110(2):196-201. PMID: 18495222.
      View in: PubMed
    86. Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DM, Yu Y, Bast RC. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer. 2008 Apr 01; 112(7):1489-502. PMID: 18286529.
      View in: PubMed
    87. Ashworth A, Balkwill F, Bast RC, Berek JS, Kaye A, Boyd JA, Mills G, Weinstein JN, Woolley K, Workman P. Opportunities and challenges in ovarian cancer research, a perspective from the 11th Ovarian cancer action/HHMT Forum, Lake Como, March 2007. Gynecol Oncol. 2008 Mar; 108(3):652-7. PMID: 18096210.
      View in: PubMed
    88. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008 Feb; 108(2):402-8. PMID: 18061248.
      View in: PubMed
    89. Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, Wenzel LB, Pazdur R. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol. 2007 Nov; 107(2):173-6. PMID: 17950384.
      View in: PubMed
    90. Le XF, Arachchige-Don AS, Mao W, Horne MC, Bast RC. Roles of human epidermal growth factor receptor 2, c-jun NH2-terminal kinase, phosphoinositide 3-kinase, and p70 S6 kinase pathways in regulation of cyclin G2 expression in human breast cancer cells. Mol Cancer Ther. 2007 Nov; 6(11):2843-57. PMID: 18025271.
      View in: PubMed
    91. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC. Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol. 2007 Dec; 107(3):526-31. PMID: 17920110.
      View in: PubMed
    92. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007 Nov 20; 25(33):5287-312. PMID: 17954709.
      View in: PubMed
    93. Moore RG, Bast RC. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol. 2007 Sep 20; 25(27):4159-61. PMID: 17698803.
      View in: PubMed
    94. Badgwell D, Lu Z, Cole L, Fritsche H, Atkinson EN, Somers E, Allard J, Moore RG, Lu KH, Bast RC. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecol Oncol. 2007 Sep; 106(3):490-7. PMID: 17532030.
      View in: PubMed
    95. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, Hunt KK, Bast RC, Shen Y, Issa JP, Yu Y. Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res. 2007; 9(4):R57. PMID: 17764565.
      View in: PubMed
    96. Badgwell D, Bast RC. Early detection of ovarian cancer. Dis Markers. 2007; 23(5-6):397-410. PMID: 18057523.
      View in: PubMed
    97. Brewer M, Ranger-Moore J, Satterfield W, Hao Z, Wang J, Brewer E, Wharton JT, Bast R, Zou C. Combination of 4-HPR and oral contraceptive in monkey model of chemoprevention of ovarian cancer. Front Biosci. 2007 Jan 01; 12:2260-8. PMID: 17127462.
      View in: PubMed
    98. Bast RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, Lu K, Lu Z, Badgwell D, Mills GB, Skates S, Zhang Z, Chan D, Lokshin A, Yu Y. Prevention and early detection of ovarian cancer: mission impossible? Recent Results Cancer Res. 2007; 174:91-100. PMID: 17302189.
      View in: PubMed
    99. Rosen DG, Mercado-Uribe I, Yang G, Bast RC, Amin HM, Lai R, Liu J. The role of constitutively active signal transducer and activator of transcription 3 in ovarian tumorigenesis and prognosis. Cancer. 2006 Dec 01; 107(11):2730-40. PMID: 17063503.
      View in: PubMed
    100. Yang G, Rosen DG, Zhang Z, Bast RC, Mills GB, Colacino JA, Mercado-Uribe I, Liu J. The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis. Proc Natl Acad Sci U S A. 2006 Oct 31; 103(44):16472-7. PMID: 17060621.
      View in: PubMed
    101. Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, Somerfield MR, Hayes DF, Bast RC. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006 Nov 20; 24(33):5313-27. PMID: 17060676.
      View in: PubMed
    102. Farley J, Bast RC, Birrer MJ. Biomarkers and clinical trial design. Gynecol Oncol. 2006 Nov; 103(2 Suppl 1):S3-5. PMID: 17027069.
      View in: PubMed
    103. Brewer M, Kirkpatrick ND, Wharton JT, Wang J, Hatch K, Auersperg N, Utzinger U, Gershenson D, Bast R, Zou C. 4-HPR modulates gene expression in ovarian cells. Int J Cancer. 2006 Sep 01; 119(5):1005-13. PMID: 16570282.
      View in: PubMed
    104. Fu S, Kavanagh JJ, Hu W, Bast RC. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gynecol Cancer. 2006 Sep-Oct; 16(5):1717-32. PMID: 17009963.
      View in: PubMed
    105. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle. 2006 Aug; 5(15):1654-61. PMID: 16861913.
      View in: PubMed
    106. Yang G, Rosen DG, Mercado-Uribe I, Colacino JA, Mills GB, Bast RC, Zhou C, Liu J. Knockdown of p53 combined with expression of the catalytic subunit of telomerase is sufficient to immortalize primary human ovarian surface epithelial cells. Carcinogenesis. 2007 Jan; 28(1):174-82. PMID: 16829690.
      View in: PubMed
    107. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC, Le XF. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene. 2006 Nov 02; 25(52):6986-96. PMID: 16715132.
      View in: PubMed
    108. Lu Z, Luo RZ, Peng H, Rosen DG, Atkinson EN, Warneke C, Huang M, Nishmoto A, Liu J, Liao WS, Yu Y, Bast RC. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer. Clin Cancer Res. 2006 Apr 15; 12(8):2404-13. PMID: 16638845.
      View in: PubMed
    109. Balkwill FR, Ashworth A, Bast RC, Berek JS, Boyd J, Disis ML, Gabra H, Gore ME, Hamilton TC, Jacobs IJ, Kaye SB, Kohn EC, Mills GB, Urban ND. 10th Biennial Helene Harris Memorial Trust meeting. Cancer Res. 2006 Mar 15; 66(6):2904-6. PMID: 16540635.
      View in: PubMed
    110. Lee Z, Swaby RF, Liang Y, Yu S, Liu S, Lu KH, Bast RC, Mills GB, Fang X. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. Cancer Res. 2006 Mar 01; 66(5):2740-8. PMID: 16510595.
      View in: PubMed
    111. Fu S, Hu W, Kavanagh JJ, Bast RC. Targeting Aurora kinases in ovarian cancer. Expert Opin Ther Targets. 2006 Feb; 10(1):77-85. PMID: 16441230.
      View in: PubMed
    112. Yu Y, Luo R, Lu Z, Wei Feng W, Badgwell D, Issa JP, Rosen DG, Liu J, Bast RC. Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. Methods Enzymol. 2006; 407:455-68. PMID: 16757345.
      View in: PubMed
    113. Rosen DG, Yang G, Bast RC, Liu J. Use of Ras-transformed human ovarian surface epithelial cells as a model for studying ovarian cancer. Methods Enzymol. 2006; 407:660-76. PMID: 16757360.
      View in: PubMed
    114. Menon U, Skates SJ, Lewis S, Rosenthal AN, Rufford B, Sibley K, Macdonald N, Dawnay A, Jeyarajah A, Bast RC, Oram D, Jacobs IJ. Prospective study using the risk of ovarian cancer algorithm to screen for ovarian cancer. J Clin Oncol. 2005 Nov 01; 23(31):7919-26. PMID: 16258091.
      View in: PubMed
    115. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, Baggerly KA, Atkinson EN, Skates S, Zhang Z, Lokshin A, Menon U, Jacobs I, Lu K. New tumor markers: CA125 and beyond. Int J Gynecol Cancer. 2005 Nov-Dec; 15 Suppl 3:274-81. PMID: 16343244.
      View in: PubMed
    116. Young T, Mei F, Liu J, Bast RC, Kurosky A, Cheng X. Proteomics analysis of H-RAS-mediated oncogenic transformation in a genetically defined human ovarian cancer model. Oncogene. 2005 Sep 08; 24(40):6174-84. PMID: 15940260.
      View in: PubMed
    117. Bast RC, Lilja H, Urban N, Rimm DL, Fritsche H, Gray J, Veltri R, Klee G, Allen A, Kim N, Gutman S, Rubin MA, Hruszkewycz A. Translational crossroads for biomarkers. Clin Cancer Res. 2005 Sep 01; 11(17):6103-8. PMID: 16144908.
      View in: PubMed
    118. Marquez RT, Baggerly KA, Patterson AP, Liu J, Broaddus R, Frumovitz M, Atkinson EN, Smith DI, Hartmann L, Fishman D, Berchuck A, Whitaker R, Gershenson DM, Mills GB, Bast RC, Lu KH. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005 Sep 01; 11(17):6116-26. PMID: 16144910.
      View in: PubMed
    119. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005 Nov; 99(2):267-77. PMID: 16061277.
      View in: PubMed
    120. Brewer M, Wharton JT, Wang J, McWatters A, Auersperg N, Gershenson D, Bast R, Zou C. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer. Gynecol Oncol. 2005 Aug; 98(2):182-92. PMID: 15907982.
      View in: PubMed
    121. Nishimoto A, Yu Y, Lu Z, Mao X, Ren Z, Watowich SS, Mills GB, Liao WS, Chen X, Bast RC, Luo RZ. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells. Cancer Res. 2005 Aug 01; 65(15):6701-10. PMID: 16061651.
      View in: PubMed
    122. Tanvetyanon T. Molecular prediction of recurrence of breast cancer. N Engl J Med. 2005 Apr 14; 352(15):1605-7; author reply 1605-7. PMID: 15832454.
      View in: PubMed
    123. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res. 2005 Mar 15; 11(6):2149-55. PMID: 15788660.
      View in: PubMed
    124. Rosen DG, Yang G, Cai KQ, Bast RC, Gershenson DM, Silva EG, Liu J. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin Cancer Res. 2005 Jan 15; 11(2 Pt 1):632-7. PMID: 15701850.
      View in: PubMed
    125. Le XF, Pruefer F, Bast RC. HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle. 2005 Jan; 4(1):87-95. PMID: 15611642.
      View in: PubMed
    126. Bast RC, Hortobagyi GN. Individualized care for patients with cancer - a work in progress. N Engl J Med. 2004 Dec 30; 351(27):2865-7. PMID: 15591336.
      View in: PubMed
    127. Le XF, Lammayot A, Gold D, Lu Y, Mao W, Chang T, Patel A, Mills GB, Bast RC. Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling. J Biol Chem. 2005 Jan 21; 280(3):2092-104. PMID: 15504738.
      View in: PubMed
    128. Rosen DG, Wang L, Jain AN, Lu KH, Luo RZ, Yu Y, Liu J, Bast RC. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival. Clin Cancer Res. 2004 Oct 01; 10(19):6559-66. PMID: 15475444.
      View in: PubMed
    129. Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004 Oct 15; 22(20):4059-66. PMID: 15381683.
      View in: PubMed
    130. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, Berchuck A, Van Haaften-Day C, Hacker NF, de Bruijn HW, van der Zee AG, Jacobs IJ, Fung ET, Chan DW. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res. 2004 Aug 15; 64(16):5882-90. PMID: 15313933.
      View in: PubMed
    131. Kelloff GJ, Bast RC, Coffey DS, D'Amico AV, Kerbel RS, Park JW, Ruddon RW, Rustin GJ, Schilsky RL, Sigman CC, Vande Woude GF. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004 Jun 01; 10(11):3881-4. PMID: 15173097.
      View in: PubMed
    132. Donato ML, Aleman A, Champlin RE, Saliba RM, Wharton JT, Burke TW, Bodurka DC, Bevers MW, Levenback CF, Wolf JK, Bast RC, Freedman RS, Ippoliti C, Brewer M, Gajewski JL, Gershenson DM. Analysis of 96 patients with advanced ovarian carcinoma treated with high-dose chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant. 2004 Jun; 33(12):1219-24. PMID: 15122311.
      View in: PubMed
    133. Rustin GJ, Bast RC, Kelloff GJ, Barrett JC, Carter SK, Nisen PD, Sigman CC, Parkinson DR, Ruddon RW. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004 Jun 01; 10(11):3919-26. PMID: 15173101.
      View in: PubMed
    134. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004 May 15; 10(10):3291-300. PMID: 15161682.
      View in: PubMed
    135. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC. A genetically defined model for human ovarian cancer. Cancer Res. 2004 Mar 01; 64(5):1655-63. PMID: 14996724.
      View in: PubMed
    136. Bast RC. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc. 2004; 115:233-47; discussion 247-8. PMID: 17060970.
      View in: PubMed
    137. Pusztai L, Krishnamurti S, Perez Cardona J, Sneige N, Esteva FJ, Volchenok M, Breitenfelder P, Kau SW, Takayama S, Krajewski S, Reed JC, Bast RC, Hortobagyi GN. Expression of BAG-1 and BcL-2 proteins before and after neoadjuvant chemotherapy of locally advanced breast cancer. Cancer Invest. 2004; 22(2):248-56. PMID: 15199607.
      View in: PubMed
    138. Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells. J Biol Chem. 2004 Mar 05; 279(10):9653-61. PMID: 14670967.
      View in: PubMed
    139. Samanta AK, Huang HJ, Bast RC, Liao WS. Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB. J Biol Chem. 2004 Feb 27; 279(9):7576-83. PMID: 14662759.
      View in: PubMed
    140. Yang G, Cai KQ, Thompson-Lanza JA, Bast RC, Liu J. Inhibition of breast and ovarian tumor growth through multiple signaling pathways by using retrovirus-mediated small interfering RNA against Her-2/neu gene expression. J Biol Chem. 2004 Feb 06; 279(6):4339-45. PMID: 14625284.
      View in: PubMed
    141. See HT, Kavanagh JJ, Hu W, Bast RC. Targeted therapy for epithelial ovarian cancer: current status and future prospects. Int J Gynecol Cancer. 2003 Nov-Dec; 13(6):701-34. PMID: 14675307.
      View in: PubMed
    142. Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer. Semin Oncol. 2003 Oct; 30(5 Suppl 16):93-104. PMID: 14613030.
      View in: PubMed
    143. Wang L, Hoque A, Luo RZ, Yuan J, Lu Z, Nishimoto A, Liu J, Sahin AA, Lippman SM, Bast RC, Yu Y. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3660-6. PMID: 14506155.
      View in: PubMed
    144. Balkwill F, Bast RC, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S, Smyth J, Ursulic S. Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust. Eur J Cancer. 2003 Sep; 39(13):1818-27. PMID: 12932658.
      View in: PubMed
    145. Tanyi JL, Hasegawa Y, Lapushin R, Morris AJ, Wolf JK, Berchuck A, Lu K, Smith DI, Kalli K, Hartmann LC, McCune K, Fishman D, Broaddus R, Cheng KW, Atkinson EN, Yamal JM, Bast RC, Felix EA, Newman RA, Mills GB. Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer. Clin Cancer Res. 2003 Sep 01; 9(10 Pt 1):3534-45. PMID: 14506139.
      View in: PubMed
    146. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, Kondo Y, Issa JP, Bast RC, Yu Y. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet. 2003 Aug 01; 12(15):1791-800. PMID: 12874100.
      View in: PubMed
    147. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, Pan Y, Kadota M, Oshimura M, Sahin AA, Issa JP, Bast RC, Yu Y. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res. 2003 Jul 15; 63(14):4174-80. PMID: 12874023.
      View in: PubMed
    148. Shvartsman HS, Lu KH, Lee J, Lillie J, Deavers MT, Clifford S, Wolf JK, Mills GB, Bast RC, Gershenson DM, Schmandt R. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003 Jul; 90(1):44-50. PMID: 12821340.
      View in: PubMed
    149. Nakamori M, Fu X, Meng F, Jin A, Tao L, Bast RC, Zhang X. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms. Clin Cancer Res. 2003 Jul; 9(7):2727-33. PMID: 12855653.
      View in: PubMed
    150. Luo RZ, Fang X, Marquez R, Liu SY, Mills GB, Liao WS, Yu Y, Bast RC. ARHI is a Ras-related small G-protein with a novel N-terminal extension that inhibits growth of ovarian and breast cancers. Oncogene. 2003 May 15; 22(19):2897-909. PMID: 12771940.
      View in: PubMed
    151. Cannistra SA, Bast RC, Berek JS, Bookman MA, Crum CP, DePriest PD, Garber JE, Koh WJ, Markman M, McGuire WP, Rose PG, Rowinsky EK, Rustin GJ, Skates SJ, Vasey PA, King L. Progress in the management of gynecologic cancer: consensus summary statement. J Clin Oncol. 2003 May 15; 21(10 Suppl):129s-132s. PMID: 12743127.
      View in: PubMed
    152. Bast RC. Status of tumor markers in ovarian cancer screening. J Clin Oncol. 2003 May 15; 21(10 Suppl):200s-205s. PMID: 12743135.
      View in: PubMed
    153. Le XF, Claret FX, Lammayot A, Tian L, Deshpande D, LaPushin R, Tari AM, Bast RC. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J Biol Chem. 2003 Jun 27; 278(26):23441-50. PMID: 12700233.
      View in: PubMed
    154. Yu Y, Fujii S, Yuan J, Luo RZ, Wang L, Bao J, Kadota M, Oshimura M, Dent SR, Issa JP, Bast RC. Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci. 2003 Mar; 983:268-77. PMID: 12724231.
      View in: PubMed
    155. Verschraegen CF, Hu W, Du Y, Mendoza J, Early J, Deavers M, Freedman RS, Bast RC, Kudelka AP, Kavanagh JJ, Giovanella BC. Establishment and characterization of cancer cell cultures and xenografts derived from primary or metastatic Mullerian cancers. Clin Cancer Res. 2003 Feb; 9(2):845-52. PMID: 12576458.
      View in: PubMed
    156. Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, Bast RC. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene. 2003 Jan 30; 22(4):484-97. PMID: 12555062.
      View in: PubMed
    157. Brewer MA, Johnson K, Follen M, Gershenson D, Bast R. Prevention of ovarian cancer: intraepithelial neoplasia. Clin Cancer Res. 2003 Jan; 9(1):20-30. PMID: 12538447.
      View in: PubMed
    158. Bast RC, Mills GB. General keynote: molecular therapeutics and pharmocogenomics. Gynecol Oncol. 2003 Jan; 88(1 Pt 2):S84-7; discussion S93-6. PMID: 12586093.
      View in: PubMed
    159. Ozols RF, Daly MB, Klein-Szanto A, Hamilton TC, Bast RC, Brewer MA. Specific keynote: chemoprevention of ovarian cancer: the journey begins. Gynecol Oncol. 2003 Jan; 88(1 Pt 2):S59-66; discussion S67-70. PMID: 12586088.
      View in: PubMed
    160. Wiener JR, Windham TC, Estrella VC, Parikh NU, Thall PF, Deavers MT, Bast RC, Mills GB, Gallick GE. Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol. 2003 Jan; 88(1):73-9. PMID: 12504632.
      View in: PubMed
    161. Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC, Gray J. Specific keynote: molecular therapeutics in ovarian cancer. Gynecol Oncol. 2003 Jan; 88(1 Pt 2):S88-92; discussion S93-6. PMID: 12586094.
      View in: PubMed
    162. Bao JJ, Le XF, Wang RY, Yuan J, Wang L, Atkinson EN, LaPushin R, Andreeff M, Fang B, Yu Y, Bast RC. Reexpression of the tumor suppressor gene ARHI induces apoptosis in ovarian and breast cancer cells through a caspase-independent calpain-dependent pathway. Cancer Res. 2002 Dec 15; 62(24):7264-72. PMID: 12499268.
      View in: PubMed
    163. Le XF, Varela CR, Bast RC. Heregulin-induced apoptosis. Apoptosis. 2002 Dec; 7(6):483-91. PMID: 12370490.
      View in: PubMed
    164. Brewer M, Utzinger U, Li Y, Atkinson EN, Satterfield W, Auersperg N, Richards-Kortum R, Follen M, Bast R. Fluorescence spectroscopy as a biomarker in a cell culture and in a nonhuman primate model for ovarian cancer chemopreventive agents. J Biomed Opt. 2002 Jan; 7(1):20-6. PMID: 11818008.
      View in: PubMed
    165. Bast RC, Urban N, Shridhar V, Smith D, Zhang Z, Skates S, Lu K, Liu J, Fishman D, Mills G. Early detection of ovarian cancer: promise and reality. Cancer Treat Res. 2002; 107:61-97. PMID: 11775462.
      View in: PubMed
    166. Le XF, Marcelli M, McWatters A, Nan B, Mills GB, O'Brian CA, Bast RC. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. Oncogene. 2001 Dec 13; 20(57):8258-69. PMID: 11781840.
      View in: PubMed
    167. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Bast RC, Hacker NF. OVX1, macrophage-colony stimulating factor, and CA-125-II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer. 2001 Dec 01; 92(11):2837-44. PMID: 11753957.
      View in: PubMed
    168. Bast RC, Mills GB, Young RC. Translational research--traffic on the bridge. Biomed Pharmacother. 2001 Nov; 55(9-10):565-71. PMID: 11769968.
      View in: PubMed
    169. Mills GB, Bast RC, Srivastava S. Future for ovarian cancer screening: novel markers from emerging technologies of transcriptional profiling and proteomics. J Natl Cancer Inst. 2001 Oct 03; 93(19):1437-9. PMID: 11584052.
      View in: PubMed
    170. Donato ML, Gershenson DM, Wharton JT, Ippoliti CM, Aleman AS, Bodurka-Bevers D, Bevers MW, Burke TW, Levenback CF, Wolf JK, Freedman RS, Bast RC, Gajewski JL, Champlin RE. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer. Gynecol Oncol. 2001 Sep; 82(3):420-6. PMID: 11520135.
      View in: PubMed
    171. Shridhar V, Lee J, Pandita A, Iturria S, Avula R, Staub J, Morrissey M, Calhoun E, Sen A, Kalli K, Keeney G, Roche P, Cliby W, Lu K, Schmandt R, Mills GB, Bast RC, James CD, Couch FJ, Hartmann LC, Lillie J, Smith DI. Genetic analysis of early- versus late-stage ovarian tumors. Cancer Res. 2001 Aug 01; 61(15):5895-904. PMID: 11479231.
      View in: PubMed
    172. Brewer M, Utzinger U, Satterfield W, Hill L, Gershenson D, Bast R, Wharton JT, Richards-Kortum R, Follen M. Biomarker modulation in a nonhuman rhesus primate model for ovarian cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. 2001 Aug; 10(8):889-93. PMID: 11489756.
      View in: PubMed
    173. Luo RZ, Peng H, Xu F, Bao J, Pang Y, Pershad R, Issa JP, Liao WS, Bast RC, Yu Y. Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI. Biochim Biophys Acta. 2001 Jun 28; 1519(3):216-22. PMID: 11418188.
      View in: PubMed
    174. Rivera E, Valero V, Syrewicz L, Rahman Z, Esteva FJ, Theriault RL, Rosales MM, Booser D, Murray JL, Bast RC, Hortobagyi GN, Esteva FL. Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer. J Clin Oncol. 2001 Mar 15; 19(6):1716-22. PMID: 11251001.
      View in: PubMed
    175. Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001 Mar 15; 19(6):1865-78. PMID: 11251019.
      View in: PubMed
    176. Schmidt M, McWatters A, White RA, Groner B, Wels W, Fan Z, Bast RC. Synergistic interaction between an anti-p185HER-2 pseudomonas exotoxin fusion protein [scFv(FRP5)-ETA] and ionizing radiation for inhibiting growth of ovarian cancer cells that overexpress HER-2. Gynecol Oncol. 2001 Feb; 80(2):145-55. PMID: 11161852.
      View in: PubMed
    177. Rodriguez GC, Haisley C, Hurteau J, Moser TL, Whitaker R, Bast RC, Stack MS. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta. Gynecol Oncol. 2001 Feb; 80(2):245-53. PMID: 11161867.
      View in: PubMed
    178. Ibrahim NK, Valero V, Rahman Z, Theriault RL, Walters RS, Buzdar AU, Booser DJ, Holmes FA, Murray JL, Willey J, Bast R, Hortobagyi GN. Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. Cancer Invest. 2001; 19(5):459-66. PMID: 11458813.
      View in: PubMed
    179. Brewer M, Utzinger U, Silva E, Gershenson D, Bast RC, Follen M, Richards-Kortum R. Fluorescence spectroscopy for in vivo characterization of ovarian tissue. Lasers Surg Med. 2001; 29(2):128-35. PMID: 11553899.
      View in: PubMed
    180. Kruzelock RP, Cuevas BD, Wiener JR, Xu FJ, Yu Y, Cabeza-Arvelaiz Y, Pershouse M, Lovell MM, Killary AM, Mills GB, Bast RC. Functional evidence for an ovarian cancer tumor suppressor gene on chromosome 22 by microcell-mediated chromosome transfer. Oncogene. 2000 Dec 14; 19(54):6277-85. PMID: 11175342.
      View in: PubMed
    181. Mao M, Fang X, Lu Y, Lapushin R, Bast RC, Mills GB. Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells. Biochem J. 2000 Dec 01; 352 Pt 2:475-82. PMID: 11085941.
      View in: PubMed
    182. Einhorn N, Bast R, Knapp R, Nilsson B, Zurawski V, Sjövall K. Long-term follow-up of the Stockholm screening study on ovarian cancer. Gynecol Oncol. 2000 Dec; 79(3):466-70. PMID: 11104621.
      View in: PubMed
    183. Hogdall EV, Høgdall CK, Tingulstad S, Hagen B, Nustad K, Xu FJ, Bast RC, Jacobs IJ. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass. Int J Cancer. 2000 Nov 20; 89(6):519-23. PMID: 11102897.
      View in: PubMed
    184. Fang X, Yu S, LaPushin R, Lu Y, Furui T, Penn LZ, Stokoe D, Erickson JR, Bast RC, Mills GB. Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase. Biochem J. 2000 Nov 15; 352 Pt 1:135-43. PMID: 11062066.
      View in: PubMed
    185. Fang X, Yu SX, Lu Y, Bast RC, Woodgett JR, Mills GB. Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A. Proc Natl Acad Sci U S A. 2000 Oct 24; 97(22):11960-5. PMID: 11035810.
      View in: PubMed
    186. Xu F, Xia W, Luo RZ, Peng H, Zhao S, Dai J, Long Y, Zou L, Le W, Liu J, Parlow AF, Hung MC, Bast RC, Yu Y. The human ARHI tumor suppressor gene inhibits lactation and growth in transgenic mice. Cancer Res. 2000 Sep 01; 60(17):4913-20. PMID: 10987306.
      View in: PubMed
    187. Xu F, Leadon SA, Yu Y, Boyer CM, O'Briant K, Ward K, McWatters A, Zhao X, Bae DS, DeSombre K, Zalutsky MR, Bast RC. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2. Clin Cancer Res. 2000 Aug; 6(8):3334-41. PMID: 10955821.
      View in: PubMed
    188. Le XF, Vadlamudi R, McWatters A, Bae DS, Mills GB, Kumar R, Bast RC. Differential signaling by an anti-p185(HER2) antibody and heregulin. Cancer Res. 2000 Jul 01; 60(13):3522-31. PMID: 10910064.
      View in: PubMed
    189. Peng H, Xu F, Pershad R, Hunt KK, Frazier ML, Berchuck A, Gray JW, Hogg D, Bast RC, Yu Y. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. Int J Cancer. 2000 Jun 01; 86(5):690-4. PMID: 10797292.
      View in: PubMed
    190. Donato ML, Gershenson D, Ippoliti C, Wharton JT, Bast RC, Aleman A, Anderlini P, Gajewski JG, Giralt S, Molldrem J, Ueno N, Lauppe J, Korbling M, Boyer J, Bodurka-Bevers D, Bevers M, Burke T, Freedman R, Levenback C, Wolf J, Champlin RE. High-dose ifosfamide and etoposide with filgrastim for stem cell mobilization in patients with advanced ovarian cancer. Bone Marrow Transplant. 2000 Jun; 25(11):1137-40. PMID: 10849525.
      View in: PubMed
    191. Le XF, McWatters A, Wiener J, Wu JY, Mills GB, Bast RC. Anti-HER2 antibody and heregulin suppress growth of HER2-overexpressing human breast cancer cells through different mechanisms. Clin Cancer Res. 2000 Jan; 6(1):260-70. PMID: 10656457.
      View in: PubMed
    192. Bösze P, Bast RC, Berchuck A, Burke HB, Buller RE, Creasman WT, Dubeau L, Fox H, Geisler HE, Geisler JP, Henson DE, Rustin GJ, Vermorken JB, Wells M, Wilbanks GD. Conseusus statements on prognostic factors in epithelial ovarian carcinoma. Report of the Consensus Meeting organized by the European Society of Gynaecological Oncology, ESGO. Eur J Gynaecol Oncol. 2000; 21(5):513-26. PMID: 11198047.
      View in: PubMed
    193. Furui T, LaPushin R, Mao M, Khan H, Watt SR, Watt MA, Lu Y, Fang X, Tsutsui S, Siddik ZH, Bast RC, Mills GB. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner. Clin Cancer Res. 1999 Dec; 5(12):4308-18. PMID: 10632375.
      View in: PubMed
    194. Gershenson DM, Deavers M, Diaz S, Tortolero-Luna G, Miller BE, Bast RC, Mills GB, Silva EG. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors. Clin Cancer Res. 1999 Dec; 5(12):4053-8. PMID: 10632339.
      View in: PubMed
    195. Fang X, Yu S, Eder A, Mao M, Bast RC, Boyd D, Mills GB. Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway. Oncogene. 1999 Nov 18; 18(48):6635-40. PMID: 10597268.
      View in: PubMed
    196. Xu F, Yu Y, Le XF, Boyer C, Mills GB, Bast RC. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. Clin Cancer Res. 1999 Nov; 5(11):3653-60. PMID: 10589783.
      View in: PubMed
    197. Pustilnik TB, Estrella V, Wiener JR, Mao M, Eder A, Watt MA, Bast RC, Mills GB. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells. Clin Cancer Res. 1999 Nov; 5(11):3704-10. PMID: 10589790.
      View in: PubMed
    198. Wolf JK, Mills GB, Bazzet L, Bast RC, Roth JA, Gershenson DM. Adenovirus-mediated p53 growth inhibition of ovarian cancer cells is independent of endogenous p53 status. Gynecol Oncol. 1999 Nov; 75(2):261-6. PMID: 10525383.
      View in: PubMed
    199. Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast R, Hortobagyi GN. Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer. 1999 Oct 01; 86(7):1251-7. PMID: 10506711.
      View in: PubMed
    200. Zalutsky MR, Xu FJ, Yu Y, Foulon CF, Zhao XG, Slade SK, Affleck DJ, Bast RC. Radioiodinated antibody targeting of the HER-2/neu oncoprotein: effects of labeling method on cellular processing and tissue distribution. Nucl Med Biol. 1999 Oct; 26(7):781-90. PMID: 10628557.
      View in: PubMed
    201. Baile WF, Kudelka AP, Beale EA, Glober GA, Myers EG, Greisinger AJ, Bast RC, Goldstein MG, Novack D, Lenzi R. Communication skills training in oncology. Description and preliminary outcomes of workshops on breaking bad news and managing patient reactions to illness. Cancer. 1999 Sep 01; 86(5):887-97. PMID: 10463990.
      View in: PubMed
    202. Mills GB, Schmandt R, Gershenson D, Bast RC. Should therapy of ovarian cancer patients be individualized based on underlying genetic defects? Clin Cancer Res. 1999 Sep; 5(9):2286-8. PMID: 10499594.
      View in: PubMed
    203. Boyer CM, Pusztai L, Wiener JR, Xu FJ, Dean GS, Bast BS, O'Briant KC, Greenwald M, DeSombre KA, Bast RC. Relative cytotoxic activity of immunotoxins reactive with different epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer. 1999 Aug 12; 82(4):525-31. PMID: 10404066.
      View in: PubMed
    204. Wiener JR, Nakano K, Kruzelock RP, Bucana CD, Bast RC, Gallick GE. Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model. Clin Cancer Res. 1999 Aug; 5(8):2164-70. PMID: 10473101.
      View in: PubMed
    205. Hogdall EV, Hogdall CK, Kjaer SK, Xu F, Yu Y, Bast RC, Blaakaer J, Jacobs IJ. OVX1 radioimmunoassay results are dependent on the method of sample collection and storage. Clin Chem. 1999 May; 45(5):692-4. PMID: 10222361.
      View in: PubMed
    206. Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, Woolas RP, Berchuck A, Madyastha KR, Bast RC. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecol Oncol. 1999 Apr; 73(1):56-61. PMID: 10094881.
      View in: PubMed
    207. Hagopian GS, Mills GB, Khokhar AR, Bast RC, Siddik ZH. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer Res. 1999 Mar; 5(3):655-63. PMID: 10100719.
      View in: PubMed
    208. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, Cuevas B, Kuo WL, Gray JW, Siciliano M, Mills GB, Bast RC. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A. 1999 Jan 05; 96(1):214-9. PMID: 9874798.
      View in: PubMed
    209. Brewer MA, Mitchell MF, Bast RC. Prevention of ovarian cancer. In Vivo. 1999 Jan-Feb; 13(1):99-106. PMID: 10218141.
      View in: PubMed
    210. Rahman Z, Kavanagh J, Champlin R, Giles R, Hanania E, Fu S, Zu Z, Mehra R, Holmes F, Kudelka A, Claxton D, Verschraegen C, Gajewski J, Andreeff M, Heimfeld S, Berenson R, Ellerson D, Calvert L, Mechetner E, Holzmayer T, Dayne A, Hamer J, Bachier C, Ostrove J, Deisseroth A, et al. Chemotherapy immediately following autologous stem-cell transplantation in patients with advanced breast cancer. Clin Cancer Res. 1998 Nov; 4(11):2717-21. PMID: 9829734.
      View in: PubMed
    211. Dean GS, Pusztai L, Xu FJ, O'Briant K, DeSombre K, Conaway M, Boyer CM, Mendelsohn J, Bast RC. Cell surface density of p185(c-erbB-2) determines susceptibility to anti-p185(c-erbB-2)-ricin A chain (RTA) immunotoxin therapy alone and in combination with anti-p170(EGFR)-RTA in ovarian cancer cells. Clin Cancer Res. 1998 Oct; 4(10):2545-50. PMID: 9796989.
      View in: PubMed
    212. Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998 Oct-Dec; 13(4):179-87. PMID: 10228898.
      View in: PubMed
    213. Gershenson DM, Burke TW, Morris M, Bast RC, Guaspari A, Hohneker J, Wharton JT. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Gynecol Oncol. 1998 Sep; 70(3):404-9. PMID: 9790795.
      View in: PubMed
    214. Bast RC, Pusztai L, Kerns BJ, MacDonald JA, Jordan P, Daly L, Boyer CM, Mendelsohn J, Berchuck A. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma. 1998 Aug; 17(4):313-21. PMID: 9790065.
      View in: PubMed
    215. Boente MP, Berchuck A, Whitaker RS, Kalén A, Xu FJ, Clarke-Pearson DL, Bell RM, Bast RC. Suppression of diacylglycerol levels by antibodies reactive with the c-erbB-2 (HER-2/neu) gene product p185c-erbB-2 in breast and ovarian cancer cell lines. Gynecol Oncol. 1998 Jul; 70(1):49-55. PMID: 9698473.
      View in: PubMed
    216. Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem. 1998 Jul; 44(7):1379-80. PMID: 9665412.
      View in: PubMed
    217. Martell RE, Xu FJ, Davis WZ, Anselmino L, Yu YH, Daly L, Bast RC. OVX1 and CEA in patients with colon carcinoma, colon polyps and benign colon disorders. Int J Biol Markers. 1998 Jul-Sep; 13(3):145-9. PMID: 10079388.
      View in: PubMed
    218. Patton SE, Martin ML, Nelsen LL, Fang X, Mills GB, Bast RC, Ostrowski MC. Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines. Cancer Res. 1998 May 15; 58(10):2253-9. PMID: 9605774.
      View in: PubMed
    219. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. Adopted on November 7, 1997 by the American Society of Clinical Oncology. J Clin Oncol. 1998 Feb; 16(2):793-5. PMID: 9469371.
      View in: PubMed
    220. Fang X, Jin X, Xu HJ, Liu L, Peng HQ, Hogg D, Roth JA, Yu Y, Xu F, Bast RC, Mills GB. Expression of p16 induces transcriptional downregulation of the RB gene. Oncogene. 1998 Jan 08; 16(1):1-8. PMID: 9467937.
      View in: PubMed
    221. Bast RC. SCC antigen. Summary remarks. Tumour Biol. 1998; 19(6):527-8. PMID: 9817982.
      View in: PubMed
    222. Pusztai L, Siddik ZH, Mills GB, Bast RC. Physiologic and pathologic drug resistance in ovarian carcinoma--a hypothesis based on a clonal progression model. Acta Oncol. 1998; 37(7-8):629-40. PMID: 10050979.
      View in: PubMed
    223. Bast RC. Summary of the first Emil J Freireich symposium. Clin Cancer Res. 1997 Dec; 3(12 Pt 2):2708-10. PMID: 10068278.
      View in: PubMed
    224. Xu HJ, Zhou Y, Ji W, Perng GS, Kruzelock R, Kong CT, Bast RC, Mills GB, Li J, Hu SX. Reexpression of the retinoblastoma protein in tumor cells induces senescence and telomerase inhibition. Oncogene. 1997 Nov 20; 15(21):2589-96. PMID: 9399646.
      View in: PubMed
    225. Xu FJ, Stack S, Boyer C, O'Briant K, Whitaker R, Mills GB, Yu YH, Bast RC. Heregulin and agonistic anti-p185(c-erbB2) antibodies inhibit proliferation but increase invasiveness of breast cancer cells that overexpress p185(c-erbB2): increased invasiveness may contribute to poor prognosis. Clin Cancer Res. 1997 Sep; 3(9):1629-34. PMID: 9815853.
      View in: PubMed
    226. Xu FJ, Yu YH, Bae DS, Zhao XG, Slade SK, Boyer CM, Bast RC, Zalutsky MR. Radioiodinated antibody targeting of the HER-2/neu oncoprotein. Nucl Med Biol. 1997 Jul; 24(5):451-9. PMID: 9290082.
      View in: PubMed
    227. Vredenburgh JJ, Silva O, Broadwater G, Berry D, DeSombre K, Tyer C, Petros WP, Peters WP, Bast RC. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant. 1997 Jun; 3(2):91-7. PMID: 9267669.
      View in: PubMed
    228. Fang X, Gibson S, Flowers M, Furui T, Bast RC, Mills GB. Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity. J Biol Chem. 1997 May 23; 272(21):13683-9. PMID: 9153219.
      View in: PubMed
    229. Beck EP, Wagner M, Anselmino L, Xu F, Bast RC, Jaeger W. Is OVX1 a suitable marker for endometrial cancer? Gynecol Oncol. 1997 May; 65(2):291-6. PMID: 9159340.
      View in: PubMed
    230. Sklaroff RB. Tumor marker guidelines. J Clin Oncol. 1997 May; 15(5):2175-6. PMID: 9164236.
      View in: PubMed
    231. Atkins CD. Guidelines for the use of carcinoembryonic antigen in colorectal cancer. J Clin Oncol. 1997 Feb; 15(2):863-4. PMID: 9053517.
      View in: PubMed
    232. Baile WF, Lenzi R, Kudelka AP, Maguire P, Novack D, Goldstein M, Myers EG, Bast RC. Improving physician-patient communication in cancer care: outcome of a workshop for oncologists. J Cancer Educ. 1997; 12(3):166-73. PMID: 9376255.
      View in: PubMed
    233. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Deisseroth AB, et al. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15346-51. PMID: 8986814.
      View in: PubMed
    234. van den Brule FA, Buicu C, Berchuck A, Bast RC, Deprez M, Liu FT, Cooper DN, Pieters C, Sobel ME, Castronovo V. Expression of the 67-kD laminin receptor, galectin-1, and galectin-3 in advanced human uterine adenocarcinoma. Hum Pathol. 1996 Nov; 27(11):1185-91. PMID: 8912829.
      View in: PubMed
    235. Hayes DF, Bast RC, Desch CE, Fritsche H, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, Ravdin P, Taube S, Winn RJ. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 1996 Oct 16; 88(20):1456-66. PMID: 8841020.
      View in: PubMed
    236. Young TN, Rodriguez GC, Rinehart AR, Bast RC, Pizzo SV, Stack MS. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. Gynecol Oncol. 1996 Jul; 62(1):89-99. PMID: 8690299.
      View in: PubMed
    237. van Haaften-Day C, Russell P, Boyer CM, Kerns BJ, Wiener JR, Jensen DN, Bast RC, Hacker NF. Expression of cell regulatory proteins in ovarian borderline tumors. Cancer. 1996 May 15; 77(10):2092-8. PMID: 8640675.
      View in: PubMed
    238. Skubitz AP, Bast RC, Wayner EA, Letourneau PC, Wilke MS. Expression of alpha 6 and beta 4 integrins in serous ovarian carcinoma correlates with expression of the basement membrane protein laminin. Am J Pathol. 1996 May; 148(5):1445-61. PMID: 8623916.
      View in: PubMed
    239. Olt G, Soper J, Ramakrishnan S, Xu F, Berchuck A, Clarke-Pearson D, Dodge R, Bast RC. Preoperative evaluation of macrophage colony-stimulating factor levels in patients with endometrial cancer. Am J Obstet Gynecol. 1996 Apr; 174(4):1316-9. PMID: 8623863.
      View in: PubMed
    240. Vredenburgh JJ, Silva O, Tyer C, DeSombre K, Abou-Ghalia A, Cook M, Layfield L, Peters WP, Bast RC. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J Hematother. 1996 Feb; 5(1):57-62. PMID: 8646482.
      View in: PubMed
    241. Franklin WA, Shpall EJ, Archer P, Johnston CS, Garza-Williams S, Hami L, Bitter MA, Bast RC, Jones RB. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat. 1996; 41(1):1-13. PMID: 8932871.
      View in: PubMed
    242. Berchuck A, Kohler MF, Bast RC. Molecular genetic features of ovarian cancer. Prog Clin Biol Res. 1996; 394:269-84. PMID: 8778801.
      View in: PubMed
    243. Tyer CL, Vredenburgh JJ, Heimer M, Peters WP, Bast RC. Breast cancer cells are effectively purged from peripheral blood progenitor cells with an immunomagnetic technique. Clin Cancer Res. 1996 Jan; 2(1):81-6. PMID: 9816094.
      View in: PubMed
    244. Nap M, Vitali A, Nustad K, Bast RC, O'Brien TJ, Nilsson O, Seguin P, Suresh MR, Børmer OP, Saga T, de Bruijn HW, Nozawa S, Kreutz FT, Jette D, Sakahara H, Gadnell M, Endo K, Barlow EH, Warren D, Paus E, Hammarström S, Kenemans P, Hilgers J. Immunohistochemical characterization of 22 monoclonal antibodies against the CA125 antigen: 2nd report from the ISOBM TD-1 Workshop. Tumour Biol. 1996; 17(6):325-31. PMID: 8938947.
      View in: PubMed
    245. Nustad K, Bast RC, Brien TJ, Nilsson O, Seguin P, Suresh MR, Saga T, Nozawa S, Børmer OP, de Bruijn HW, Nap M, Vitali A, Gadnell M, Clark J, Shigemasa K, Karlsson B, Kreutz FT, Jette D, Sakahara H, Endo K, Paus E, Warren D, Hammarström S, Kenemans P, Hilgers J. Specificity and affinity of 26 monoclonal antibodies against the CA 125 antigen: first report from the ISOBM TD-1 workshop. International Society for Oncodevelopmental Biology and Medicine. Tumour Biol. 1996; 17(4):196-219. PMID: 8685601.
      View in: PubMed
    246. Vredenburgh JJ, Peters WP, Rosner G, DeSombre K, Johnston WW, Kamel A, Wu K, Bast RC. Detection of tumor cells in the bone marrow of stage IV breast cancer patients receiving high-dose chemotherapy: the role of induction chemotherapy. Bone Marrow Transplant. 1995 Dec; 16(6):815-21. PMID: 8750275.
      View in: PubMed
    247. Berek JS, Bast RC. Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995 Nov 15; 76(10 Suppl):2092-6. PMID: 8635006.
      View in: PubMed
    248. Skates SJ, Xu FJ, Yu YH, Sjövall K, Einhorn N, Chang Y, Bast RC, Knapp RC. Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers. Cancer. 1995 Nov 15; 76(10 Suppl):2004-10. PMID: 8634992.
      View in: PubMed
    249. Hurteau JA, Woolas RP, Jacobs IJ, Oram DC, Kurman CC, Rubin LA, Nelson DL, Berchuck A, Bast RC, Mills GB. Soluble interleukin-2 receptor alpha is elevated in sera of patients with benign ovarian neoplasms and epithelial ovarian cancer. Cancer. 1995 Nov 01; 76(9):1615-20. PMID: 8635066.
      View in: PubMed
    250. Berchuck A, Bast RC. p53-based gene therapy of ovarian cancer: magic bullet? Gynecol Oncol. 1995 Nov; 59(2):169-70. PMID: 7590466.
      View in: PubMed
    251. Woolas RP, Conaway MR, Xu F, Jacobs IJ, Yu Y, Daly L, Davies AP, O'Briant K, Berchuck A, Soper JT, et al. Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol. 1995 Oct; 59(1):111-6. PMID: 7557595.
      View in: PubMed
    252. Portela A, Cornélissen G, Halberg F, Bast RC, Fujii S, Xu F, Yu Y, Takagi M, Halberg J, Halberg F, et al. Spectral differences between epitopes in the cronomes of salivary CA130 and CA125. In Vivo. 1995 Jul-Aug; 9(4):341-6. PMID: 8555433.
      View in: PubMed
    253. Xu F, Yu Y, Bast RC, Cornélissen G, Fujii S, Takagi M, O'Brien T, Halberg F. Toward salivary-urinary chronosensitivity testing: chronomes of OVX1, M-CSF and CA130. In Vivo. 1995 Jul-Aug; 9(4):407-12. PMID: 8555442.
      View in: PubMed
    254. Havrilesky LJ, Hurteau JA, Whitaker RS, Elbendary A, Wu S, Rodriguez GC, Bast RC, Berchuck A. Regulation of apoptosis in normal and malignant ovarian epithelial cells by transforming growth factor beta. Cancer Res. 1995 Feb 15; 55(4):944-8. PMID: 7531618.
      View in: PubMed
    255. Bast RC, Boyer CM, Xu FJ, Wiener J, Dabel R, Woolas R, Jacobs I, Berchuck A. Molecular approaches to prevention and detection of epithelial ovarian cancer. J Cell Biochem Suppl. 1995; 23:219-22. PMID: 8747399.
      View in: PubMed
    256. Bast RC. Clinical and laboratory directions for ovarian cancer research. Gynecol Oncol. 1994 Dec; 55(3 Pt 2):S164-7. PMID: 7835802.
      View in: PubMed
    257. Elbendary A, Berchuck A, Davis P, Havrilesky L, Bast RC, Iglehart JD, Marks JR. Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent of the p53 pathway in ovarian cancer cells. Cell Growth Differ. 1994 Dec; 5(12):1301-7. PMID: 7696178.
      View in: PubMed
    258. Xu FJ, Boyer CM, Bae DS, Wu S, Greenwald M, O'Briant K, Yu YH, Mills GB, Bast RC. The tyrosine kinase activity of the C-erbB-2 gene product (p185) is required for growth inhibition by anti-p185 antibodies but not for the cytotoxicity of an anti-p185-ricin-A chain immunotoxin. Int J Cancer. 1994 Oct 15; 59(2):242-7. PMID: 7927925.
      View in: PubMed
    259. McGeehan GM, Becherer JD, Bast RC, Boyer CM, Champion B, Connolly KM, Conway JG, Furdon P, Karp S, Kidao S, et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature. 1994 Aug 18; 370(6490):558-61. PMID: 8052311.
      View in: PubMed
    260. Hurteau J, Rodriguez GC, Whitaker RS, Shah S, Mills G, Bast RC, Berchuck A. Transforming growth factor-beta inhibits proliferation of human ovarian cancer cells obtained from ascites. Cancer. 1994 Jul 01; 74(1):93-9. PMID: 8004589.
      View in: PubMed
    261. Berchuck A, Elbendary A, Havrilesky L, Rodriguez GC, Bast RC. Pathogenesis of ovarian cancers. J Soc Gynecol Investig. 1994 Jul-Sep; 1(3):181-90. PMID: 9419769.
      View in: PubMed
    262. Shpall EJ, Stemmer SM, Hami L, Franklin WA, Shaw L, Bonner HS, Bearman SI, Peters WP, Bast RC, McCulloch W, et al. Amifostine (WR-2721) shortens the engraftment period of 4-hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support. Blood. 1994 Jun 01; 83(11):3132-7. PMID: 8193351.
      View in: PubMed
    263. Lukes AS, Kohler MF, Pieper CF, Kerns BJ, Bentley R, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC, Berchuck A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer. 1994 May 01; 73(9):2380-5. PMID: 7909491.
      View in: PubMed
    264. Young TN, Rodriguez GC, Moser TL, Bast RC, Pizzo SV, Stack MS. Coordinate expression of urinary-type plasminogen activator and its receptor accompanies malignant transformation of the ovarian surface epithelium. Am J Obstet Gynecol. 1994 May; 170(5 Pt 1):1285-96. PMID: 8178854.
      View in: PubMed
    265. Wu S, Meeker WA, Wiener JR, Berchuck A, Bast RC, Boyer CM. Transfection of ovarian cancer cells with tumor necrosis factor-alpha (TNF-alpha) antisense mRNA abolishes the proliferative response to interleukin-1 (IL-1) but not TNF-alpha. Gynecol Oncol. 1994 Apr; 53(1):59-63. PMID: 8175024.
      View in: PubMed
    266. Campbell IG, Nicolai HM, Foulkes WD, Senger G, Stamp GW, Allan G, Boyer C, Jones K, Bast RC, Solomon E. A novel gene encoding a B-box protein within the BRCA1 region at 17q21.1. Hum Mol Genet. 1994 Apr; 3(4):589-94. PMID: 8069304.
      View in: PubMed
    267. Xu FJ, Yu YH, Daly L, Anselmino L, Hass GM, Berchuck A, Rodriguez GC, Soper JT, Clarke-Pearson DL, Hollis D, et al. OVX1 as a marker for early stage endometrial carcinoma. Cancer. 1994 Apr 01; 73(7):1855-8. PMID: 8137210.
      View in: PubMed
    268. Wiener JR, Hurteau JA, Kerns BJ, Whitaker RS, Conaway MR, Berchuck A, Bast RC. Overexpression of the tyrosine phosphatase PTP1B is associated with human ovarian carcinomas. Am J Obstet Gynecol. 1994 Apr; 170(4):1177-83. PMID: 8166206.
      View in: PubMed
    269. Wiener JR, Kerns BJ, Harvey EL, Conaway MR, Iglehart JD, Berchuck A, Bast RC. Overexpression of the protein tyrosine phosphatase PTP1B in human breast cancer: association with p185c-erbB-2 protein expression. J Natl Cancer Inst. 1994 Mar 02; 86(5):372-8. PMID: 7905928.
      View in: PubMed
    270. Moser TL, Young TN, Rodriguez GC, Pizzo SV, Bast RC, Stack MS. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer. 1994 Feb 15; 56(4):552-9. PMID: 8112891.
      View in: PubMed
    271. Kerns BJ, Jordan PA, Faerman LL, Berchuck A, Bast RC, Layfield LJ. Determination of proliferation index with MIB-1 in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol. 1994 Feb; 101(2):192-7. PMID: 8116574.
      View in: PubMed
    272. Berchuck A, Kohler MF, Hopkins MP, Humphrey PA, Robboy SJ, Rodriguez GC, Soper JT, Clarke-Pearson DL, Bast RC. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol. 1994 Feb; 52(2):232-6. PMID: 7508877.
      View in: PubMed
    273. Bast RC, Xu F, Yu Y, Crews J, Argon Y, Maier L, Lidor Y, Berchuck A, Boyer CM. Additive and synergistic interactions of monoclonal antibodies and immunotoxins reactive with breast and ovarian cancer. Immunol Ser. 1994; 61:23-30. PMID: 7912111.
      View in: PubMed
    274. Liu FS, Kohler MF, Marks JR, Bast RC, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol. 1994 Jan; 83(1):118-24. PMID: 8272291.
      View in: PubMed
    275. van den Brûle FA, Berchuck A, Bast RC, Liu FT, Gillet C, Sobel ME, Castronovo V. Differential expression of the 67-kD laminin receptor and 31-kD human laminin-binding protein in human ovarian carcinomas. Eur J Cancer. 1994; 30A(8):1096-9. PMID: 7654437.
      View in: PubMed
    276. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol. 1994 Jan; 170(1 Pt 1):246-52. PMID: 8296829.
      View in: PubMed
    277. Jacobs IJ, Rivera H, Oram DH, Bast RC. Differential diagnosis of ovarian cancer with tumour markers CA 125, CA 15-3 and TAG 72.3. Br J Obstet Gynaecol. 1993 Dec; 100(12):1120-4. PMID: 8297846.
      View in: PubMed
    278. Woolas RP, Xu FJ, Jacobs IJ, Yu YH, Daly L, Berchuck A, Soper JT, Clarke-Pearson DL, Oram DH, Bast RC. Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst. 1993 Nov 03; 85(21):1748-51. PMID: 8411259.
      View in: PubMed
    279. Bast RC. Perspectives on the future of cancer markers. Clin Chem. 1993 Nov; 39(11 Pt 2):2444-51. PMID: 8222257.
      View in: PubMed
    280. Lidor YJ, O'Briant KC, Xu FJ, Hamilton TC, Ozols RF, Bast RC. Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action. J Clin Invest. 1993 Nov; 92(5):2440-7. PMID: 8227359.
      View in: PubMed
    281. Bast RC. Progress in radioimmunotherapy. N Engl J Med. 1993 Oct 21; 329(17):1266-8. PMID: 8413396.
      View in: PubMed
    282. Kohler MF, Marks JR, Wiseman RW, Jacobs IJ, Davidoff AM, Clarke-Pearson DL, Soper JT, Bast RC, Berchuck A. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst. 1993 Sep 15; 85(18):1513-9. PMID: 8360934.
      View in: PubMed
    283. Kohler MF, Nishii H, Humphrey PA, Saski H, Marks J, Bast RC, Clarke-Pearson DL, Boyd J, Berchuck A. Mutation of the p53 tumor-suppressor gene is not a feature of endometrial hyperplasias. Am J Obstet Gynecol. 1993 Sep; 169(3):690-4. PMID: 8372881.
      View in: PubMed
    284. Boente MP, Hurteau J, Rodriguez GC, Bast RC, Berchuck A. The biology of ovarian cancer. Curr Opin Oncol. 1993 Sep; 5(5):900-7. PMID: 8218503.
      View in: PubMed
    285. Gallion HH, Bast RC. National Cancer Institute Conference on Investigational Strategies for Detection and Intervention in Early Ovarian Cancer. Cancer Res. 1993 Aug 15; 53(16):3839-42. PMID: 8339296.
      View in: PubMed
    286. Lidor YJ, Xu FJ, Martínez-Maza O, Olt GJ, Marks JR, Berchuck A, Ramakrishnan S, Berek JS, Bast RC. Constitutive production of macrophage colony-stimulating factor and interleukin-6 by human ovarian surface epithelial cells. Exp Cell Res. 1993 Aug; 207(2):332-9. PMID: 8344385.
      View in: PubMed
    287. Xu FJ, Yu YH, Daly L, DeSombre K, Anselmino L, Hass GM, Berchuck A, Soper JT, Clarke-Pearson DL, Boyer C, et al. OVX1 radioimmunoassay complements CA-125 for predicting the presence of residual ovarian carcinoma at second-look surgical surveillance procedures. J Clin Oncol. 1993 Aug; 11(8):1506-10. PMID: 8336189.
      View in: PubMed
    288. Bast R, Woolas R. Screening for ovarian cancer. Multiple markers may outperform CA 125 alone. BMJ. 1993 Jun 19; 306(6893):1684-5. PMID: 8324445.
      View in: PubMed
    289. McKenzie SJ, DeSombre KA, Bast BS, Hollis DR, Whitaker RS, Berchuck A, Boyer CM, Bast RC. Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer. Cancer. 1993 Jun 15; 71(12):3942-6. PMID: 8099528.
      View in: PubMed
    290. Jordan PA, Kerns BJ, Pence JC, Kohler MF, Bast RC, Kinney RB, Berchuck A. Determination of proliferation index in advanced ovarian cancer using quantitative image analysis. Am J Clin Pathol. 1993 Jun; 99(6):736-40. PMID: 8322710.
      View in: PubMed
    291. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, Kurtzberg J, Bast RC, Jones R, Shpall E, et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol. 1993 Jun; 11(6):1132-43. PMID: 8501500.
      View in: PubMed
    292. Kohler MF, Kerns BJ, Humphrey PA, Marks JR, Bast RC, Berchuck A. Mutation and overexpression of p53 in early-stage epithelial ovarian cancer. Obstet Gynecol. 1993 May; 81(5 ( Pt 1)):643-50. PMID: 8469448.
      View in: PubMed
    293. Wu S, Boyer CM, Whitaker RS, Berchuck A, Wiener JR, Weinberg JB, Bast RC. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res. 1993 Apr 15; 53(8):1939-44. PMID: 8385577.
      View in: PubMed
    294. Jacobs IJ, Smith SA, Wiseman RW, Futreal PA, Harrington T, Osborne RJ, Leech V, Molyneux A, Berchuck A, Ponder BA, et al. A deletion unit on chromosome 17q in epithelial ovarian tumors distal to the familial breast/ovarian cancer locus. Cancer Res. 1993 Mar 15; 53(6):1218-21. PMID: 8095178.
      View in: PubMed
    295. Bast RC, Boyer CM, Jacobs I, Xu FJ, Wu S, Wiener J, Kohler M, Berchuck A. Cell growth regulation in epithelial ovarian cancer. Cancer. 1993 Feb 15; 71(4 Suppl):1597-601. PMID: 8431895.
      View in: PubMed
    296. Xu F, Lupu R, Rodriguez GC, Whitaker RS, Boente MP, Berchuck A, Yu Y, DeSombre KA, Boyer CM, Bast RC. Antibody-induced growth inhibition is mediated through immunochemically and functionally distinct epitopes on the extracellular domain of the c-erbB-2 (HER-2/neu) gene product p185. Int J Cancer. 1993 Feb 01; 53(3):401-8. PMID: 7679090.
      View in: PubMed
    297. Berchuck A, Kohler MF, Boente MP, Rodriguez GC, Whitaker RS, Bast RC. Growth regulation and transformation of ovarian epithelium. Cancer. 1993 Jan 15; 71(2 Suppl):545-51. PMID: 8420675.
      View in: PubMed
    298. Rodríguez GC, Boente MP, Berchuck A, Whitaker RS, O'Briant KC, Xu F, Bast RC. The effect of antibodies and immunotoxins reactive with HER-2/neu on growth of ovarian and breast cancer cell lines. Am J Obstet Gynecol. 1993 Jan; 168(1 Pt 1):228-32. PMID: 8420332.
      View in: PubMed
    299. Jacobs IJ, Kohler MF, Wiseman RW, Marks JR, Whitaker R, Kerns BA, Humphrey P, Berchuck A, Ponder BA, Bast RC. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst. 1992 Dec 02; 84(23):1793-8. PMID: 1433368.
      View in: PubMed
    300. Boente MP, Berchuck A, Rodriguez GC, Davidoff A, Whitaker R, Xu FJ, Marks J, Clarke-Pearson DL, Bast RC. The effect of interferon gamma on epidermal growth factor receptor expression in normal and malignant ovarian epithelial cells. Am J Obstet Gynecol. 1992 Dec; 167(6):1877-82. PMID: 1361720.
      View in: PubMed
    301. Olt G, Berchuck A, Soisson AP, Boyer CM, Bast RC. Fibronectin is an immunosuppressive substance associated with epithelial ovarian cancer. Cancer. 1992 Oct 15; 70(8):2137-42. PMID: 1394043.
      View in: PubMed
    302. Wiener JR, Berchuck A, Bast RC. Biology and therapy with biologic agents in gynecologic cancer. Curr Opin Oncol. 1992 Oct; 4(5):946-54. PMID: 1457511.
      View in: PubMed
    303. Jacobs IJ, Oram DH, Bast RC. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet Gynecol. 1992 Sep; 80(3 Pt 1):396-9. PMID: 1495694.
      View in: PubMed
    304. Pence JC, Deutsch MA, Kerns BJ, Huper G, Jordan LK, Wolfe WG, Samuelson WM, Fulkerson WJ, Dodge RK, Plate CA, et al. Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. Cancer. 1992 Sep 01; 70(5):1115-23. PMID: 1515986.
      View in: PubMed
    305. Berchuck A, Kohler MF, Bast RC. Oncogenes in ovarian cancer. Hematol Oncol Clin North Am. 1992 Aug; 6(4):813-27. PMID: 1500387.
      View in: PubMed
    306. Crews JR, Maier LA, Yu YH, Hester S, O'Briant K, Leslie DS, DeSombre K, George SL, Boyer CM, Argon Y, et al. A combination of two immunotoxins exerts synergistic cytotoxic activity against human breast-cancer cell lines. Int J Cancer. 1992 Jul 09; 51(5):772-9. PMID: 1351885.
      View in: PubMed
    307. Einhorn N, Sjövall K, Knapp RC, Hall P, Scully RE, Bast RC, Zurawski VR. Prospective evaluation of serum CA 125 levels for early detection of ovarian cancer. Obstet Gynecol. 1992 Jul; 80(1):14-8. PMID: 1603484.
      View in: PubMed
    308. Daly L, Ferguson J, Cram GP, Hars V, George SL, McCarty KS, Bast RC. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen. J Clin Oncol. 1992 Jul; 10(7):1057-65. PMID: 1607912.
      View in: PubMed
    309. Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem. 1992 Jul; 40(7):1047-51. PMID: 1607637.
      View in: PubMed
    310. Cornélissen G, Halberg F, Halberg E, Bingham C, Haus E, Bast RC, Fujii S, Long HJ, Halberg F, Tamura K. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy. Chronobiologia. 1992 Jul-Dec; 19(3-4):131-49. PMID: 1362146.
      View in: PubMed
    311. Deutsch MA, Pence JC, Kerns BJ, Plate CA, Kinney R, Gooch G, Iglehart JD, Bast RC. Detection of a novel marker in the bronchial secretions of patients with non-small cell lung cancer using the 4B5 monoclonal antibody. Cancer. 1992 Jun 15; 69(12):2894-904. PMID: 1375528.
      View in: PubMed
    312. O'Briant K, Chrysson N, Hunter V, Tyson F, Tanner M, Daly L, George SL, Berchuck A, Soper J, Fowler W, et al. Ha-ras polymorphisms in epithelial ovarian cancer. Gynecol Oncol. 1992 Jun; 45(3):299-302. PMID: 1351862.
      View in: PubMed
    313. Bast RC, Jacobs I, Berchuck A. Malignant transformation of ovarian epithelium. J Natl Cancer Inst. 1992 Apr 15; 84(8):556-8. PMID: 1556762.
      View in: PubMed
    314. Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC, Marks JR. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992 Mar 15; 52(6):1622-7. PMID: 1540970.
      View in: PubMed
    315. Berchuck A, Boente MP, Bast RC. The use of tumor markers in the management of patients with gynecologic carcinomas. Clin Obstet Gynecol. 1992 Mar; 35(1):45-54. PMID: 1544249.
      View in: PubMed
    316. Wu S, Rodabaugh K, Martinez-Maza O, Watson JM, Silberstein DS, Boyer CM, Peters WP, Weinberg JB, Berek JS, Bast RC. Stimulation of ovarian tumor cell proliferation with monocyte products including interleukin-1, interleukin-6, and tumor necrosis factor-alpha. Am J Obstet Gynecol. 1992 Mar; 166(3):997-1007. PMID: 1550178.
      View in: PubMed
    317. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA, Clarke-Pearson DL, Bast RC. Regulation of growth of normal ovarian epithelial cells and ovarian cancer cell lines by transforming growth factor-beta. Am J Obstet Gynecol. 1992 Feb; 166(2):676-84. PMID: 1536252.
      View in: PubMed
    318. Johnston CS, Shpall EJ, Williams S, Hami L, Jones RB, Bast RC, Ceriani RL, Franklin W. Detection of minimal residual breast cancer in bone marrow. Prog Clin Biol Res. 1992; 377:637-42. PMID: 1438446.
      View in: PubMed
    319. Berchuck A, Boente MP, Kerns BJ, Kinney RB, Soper JT, Clarke-Pearson DL, Bast RC, Bacus SS. Ploidy analysis of epithelial ovarian cancers using image cytometry. Gynecol Oncol. 1992 Jan; 44(1):61-5. PMID: 1370427.
      View in: PubMed
    320. Lidor YJ, Shpall EJ, Peters WP, Bast RC. Synergistic cytotoxicity of different alkylating agents for epithelial ovarian cancer. Int J Cancer. 1991 Nov 11; 49(5):704-10. PMID: 1937956.
      View in: PubMed
    321. Xu FJ, Ramakrishnan S, Daly L, Soper JT, Berchuck A, Clarke-Pearson D, Bast RC. Increased serum levels of macrophage colony-stimulating factor in ovarian cancer. Am J Obstet Gynecol. 1991 Nov; 165(5 Pt 1):1356-62. PMID: 1957862.
      View in: PubMed
    322. Bast RC, Knauf S, Epenetos A, Dhokia B, Daly L, Tanner M, Soper J, Creasman W, Gall S, Knapp RC, et al. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 1991 Oct 15; 68(8):1758-63. PMID: 1913520.
      View in: PubMed
    323. Maier LA, Xu FJ, Hester S, Boyer CM, McKenzie S, Bruskin AM, Argon Y, Bast RC. Requirements for the internalization of a murine monoclonal antibody directed against the HER-2/neu gene product c-erbB-2. Cancer Res. 1991 Oct 01; 51(19):5361-9. PMID: 1680547.
      View in: PubMed
    324. Bast RC, Capizzi RL, Pagano JS, Wiley AL. Insurance coverage of screening mammography and Pap smears. The directors of North Carolina's University-based cancer centers speak out. N C Med J. 1991 Oct; 52(10):496-8. PMID: 1944619.
      View in: PubMed
    325. O'Briant KC, Shpall EJ, Houston LL, Peters WP, Bast RC. Elimination of clonogenic breast cancer cells from human bone marrow. A comparison of immunotoxin treatment with chemoimmunoseparation using 4-hydroperoxycyclophosphamide, monoclonal antibodies, and magnetic microspheres. Cancer. 1991 Sep 15; 68(6):1272-8. PMID: 1873781.
      View in: PubMed
    326. Tyson FL, Boyer CM, Kaufman R, O'Briant K, Cram G, Crews JR, Soper JT, Daly L, Fowler WC, Haskill JS, et al. Expression and amplification of the HER-2/neu (c-erbB-2) protooncogene in epithelial ovarian tumors and cell lines. Am J Obstet Gynecol. 1991 Sep; 165(3):640-6. PMID: 1679963.
      View in: PubMed
    327. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IF, Bast RC, Finn OJ. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 1991 Jun 01; 51(11):2908-16. PMID: 1709586.
      View in: PubMed
    328. Ozols RF, Hamilton TC, Hoskins WJ, Bast RC, Young RC. Summary of symposium: Biology and therapy of ovarian cancer. Semin Oncol. 1991 Jun; 18(3):297-306. PMID: 2042066.
      View in: PubMed
    329. Bookman MA, Bast RC. The immunobiology and immunotherapy of ovarian cancer. Semin Oncol. 1991 Jun; 18(3):270-91. PMID: 1710393.
      View in: PubMed
    330. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res. 1991 Jun 01; 51(11):2979-84. PMID: 2032235.
      View in: PubMed
    331. Rodriguez GC, Berchuck A, Whitaker RS, Schlossman D, Clarke-Pearson DL, Bast RC. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. II. Relationship between receptor expression and response to epidermal growth factor. Am J Obstet Gynecol. 1991 Mar; 164(3):745-50. PMID: 2003535.
      View in: PubMed
    332. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol. 1991 Feb; 164(2):669-74. PMID: 1992720.
      View in: PubMed
    333. Shpall EJ, Bast RC, Joines WT, Jones RB, Anderson I, Johnston C, Eggleston S, Tepperberg M, Edwards S, Peters WP. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant. 1991 Feb; 7(2):145-51. PMID: 2049558.
      View in: PubMed
    334. Yu YH, Schlossman DM, Harrison CL, Rhinehardt-Clark A, Soper JT, Klug TL, Zurawski VR, Bast RC. Coexpression of different antigenic markers on moieties that bear CA 125 determinants. Cancer Res. 1991 Jan 15; 51(2):468-75. PMID: 1702359.
      View in: PubMed
    335. Berchuck A, Rodriguez G, Kinney RB, Soper JT, Dodge RK, Clarke-Pearson DL, Bast RC. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol. 1991 Jan; 164(1 Pt 1):15-21. PMID: 1670908.
      View in: PubMed
    336. Shpall EJ, Jones RB, Bast RC, Rosner GL, Vandermark R, Ross M, Affronti ML, Johnston C, Eggleston S, Tepperburg M, et al. 4-Hydroperoxycyclophosphamide purging of breast cancer from the mononuclear cell fraction of bone marrow in patients receiving high-dose chemotherapy and autologous marrow support: a phase I trial. J Clin Oncol. 1991 Jan; 9(1):85-93. PMID: 1985173.
      View in: PubMed
    337. Harlozinska A, Bar JK, Rabczynski J, Bast RC, Richter R, Cislo M. Reactivity of polyclonal and two monoclonal antibodies with cell subsets isolated from cystic fluids of ovarian serous neoplasms. Tumori. 1990 Oct 31; 76(5):505-10. PMID: 1701581.
      View in: PubMed
    338. Soper JT, Berchuck A, Olt GJ, Soisson AP, Clarke-Pearson DL, Bast RC. Preoperative evaluation of serum CA 125, TAG 72, and CA 15-3 in patients with endometrial carcinoma. Am J Obstet Gynecol. 1990 Oct; 163(4 Pt 1):1204-9. PMID: 2220931.
      View in: PubMed
    339. Hunter VJ, Daly L, Helms M, Soper JT, Berchuck A, Clarke-Pearson DL, Bast RC. The prognostic significance of CA 125 half-life in patients with ovarian cancer who have received primary chemotherapy after surgical cytoreduction. Am J Obstet Gynecol. 1990 Oct; 163(4 Pt 1):1164-7. PMID: 2171337.
      View in: PubMed
    340. Westhoff C, Gollub E, Patel J, Rivera H, Bast R. CA 125 levels in menopausal women. Obstet Gynecol. 1990 Sep; 76(3 Pt 1):428-31. PMID: 2381621.
      View in: PubMed
    341. Shpall EJ, Clarke-Pearson D, Soper JT, Berchuck A, Jones RB, Bast RC, Ross M, Lidor Y, Vanacek K, Tyler T, et al. High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer. Gynecol Oncol. 1990 Sep; 38(3):386-91. PMID: 2121627.
      View in: PubMed
    342. Olt G, Berchuck A, Bast RC. The role of tumor markers in gynecologic oncology. Obstet Gynecol Surv. 1990 Sep; 45(9):570-7. PMID: 1697940.
      View in: PubMed
    343. Berchuck A, Rodriguez G, Kamel A, Soper JT, Clarke-Pearson DL, Bast RC. Expression of epidermal growth factor receptor and HER-2/neu in normal and neoplastic cervix, vulva, and vagina. Obstet Gynecol. 1990 Sep; 76(3 Pt 1):381-7. PMID: 1974342.
      View in: PubMed
    344. Jones RB, Shpall EJ, Shogan J, Affronti ML, Coniglio D, Hart L, Halperin E, Iglehart JD, Moore J, Gockerman J, et al. The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. Cancer. 1990 Aug 01; 66(3):431-6. PMID: 2364358.
      View in: PubMed
    345. Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res. 1990 Jul 01; 50(13):4087-91. PMID: 1972347.
      View in: PubMed
    346. Welch WR, Niloff JM, Anderson D, Battaile A, Emery S, Knapp RC, Bast RC. Antigenic heterogeneity in human ovarian cancer. Gynecol Oncol. 1990 Jul; 38(1):12-6. PMID: 2162315.
      View in: PubMed
    347. Leslie DS, Johnston WW, Daly L, Ring DB, Shpall EJ, Peters WP, Bast RC. Detection of breast carcinoma cells in human bone marrow using fluorescence-activated cell sorting and conventional cytology. Am J Clin Pathol. 1990 Jul; 94(1):8-13. PMID: 2193508.
      View in: PubMed
    348. Yu YH. [Synergistic antitumor activity of human breast cancer immunotoxins]. Zhonghua Zhong Liu Za Zhi. 1990 Jul; 12(4):246-50. PMID: 2272257.
      View in: PubMed
    349. Montgomery RB, Kurtzberg J, Rhinehardt-Clark A, Haleen A, Ramakrishnan S, Olsen GA, Peters WP, Smith CA, Haynes BF, Houston LL, et al. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin. Bone Marrow Transplant. 1990 Jun; 5(6):395-402. PMID: 2369680.
      View in: PubMed
    350. Yu YH, Crews JR, Cooper K, Ramakrishnan S, Houston LL, Leslie DS, George SL, Lidor Y, Boyer CM, Ring DB, et al. Use of immunotoxins in combination to inhibit clonogenic growth of human breast carcinoma cells. Cancer Res. 1990 Jun 01; 50(11):3231-8. PMID: 2334918.
      View in: PubMed
    351. Berchuck A, Olt GJ, Soisson AP, Kamel A, Soper JT, Boyer CM, Clarke-Pearson DL, Leslie DS, Bast RC. Heterogeneity of antigen expression in advanced epithelial ovarian cancer. Am J Obstet Gynecol. 1990 Apr; 162(4):883-8. PMID: 2327461.
      View in: PubMed
    352. Zurawski VR, Sjovall K, Schoenfeld DA, Broderick SF, Hall P, Bast RC, Eklund G, Mattsson B, Connor RJ, Prorok PC, et al. Prospective evaluation of serum CA 125 levels in a normal population, phase I: the specificities of single and serial determinations in testing for ovarian cancer. Gynecol Oncol. 1990 Mar; 36(3):299-305. PMID: 2318438.
      View in: PubMed
    353. Hunter VJ, Weinberg JB, Haney AF, Soper JT, Lavin P, Metsch L, Knapp RC, Bast RC. CA 125 in peritoneal fluid and serum from patients with benign gynecologic conditions and ovarian cancer. Gynecol Oncol. 1990 Feb; 36(2):161-5. PMID: 2404835.
      View in: PubMed
    354. Soper JT, Hunter VJ, Daly L, Tanner M, Creasman WT, Bast RC. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol. 1990 Feb; 75(2):249-54. PMID: 2300353.
      View in: PubMed
    355. Berchuck A, Olt GJ, Everitt L, Soisson AP, Bast RC, Boyer CM. The role of peptide growth factors in epithelial ovarian cancer. Obstet Gynecol. 1990 Feb; 75(2):255-62. PMID: 2300354.
      View in: PubMed
    356. Shpall EJ, Anderson IC, Bast RC, Joines WT, Jones RB, Ross M, Edwards S, Eggleston S, Johnston C, Tepperberg M, et al. Immunopharmacologic purging of breast cancer from bone marrow for autologous bone marrow transplantation. Prog Clin Biol Res. 1990; 333:321-35; discussion 336. PMID: 2308989.
      View in: PubMed
    357. Olt GJ, Berchuck A, Bast RC. Gynecologic tumor markers. Semin Surg Oncol. 1990; 6(6):305-13. PMID: 2263805.
      View in: PubMed
    358. Jacobs I, Bast RC. Immunodiagnosis of ovarian tumors. Immunol Ser. 1990; 53:323-38. PMID: 2100566.
      View in: PubMed
    359. Sallan SE, Niemeyer CM, Billett AL, Lipton JM, Tarbell NJ, Gelber RD, Murray C, Pittinger TP, Wolfe LC, Bast RC, et al. Autologous bone marrow transplantation for acute lymphoblastic leukemia. J Clin Oncol. 1989 Nov; 7(11):1594-601. PMID: 2809677.
      View in: PubMed
    360. Soisson AP, Berchuck A, Lessey BA, Soper JT, Clarke-Pearson DL, McCarty KS, Bast RC. Immunohistochemical expression of TAG-72 in normal and malignant endometrium: correlation of antigen expression with estrogen receptor and progesterone receptor levels. Am J Obstet Gynecol. 1989 Nov; 161(5):1258-63. PMID: 2589448.
      View in: PubMed
    361. Berchuck A, Soisson AP, Olt GJ, Soper JT, Clarke-Pearson DL, Bast RC, McCarty KS. Epidermal growth factor receptor expression in normal and malignant endometrium. Am J Obstet Gynecol. 1989 Nov; 161(5):1247-52. PMID: 2480065.
      View in: PubMed
    362. Berchuck A, Soisson AP, Soper JT, Clarke-Pearson DL, Bast RC, McCarty KS. Reactivity of epidermal growth factor receptor monoclonal antibodies with human uterine tissues. Arch Pathol Lab Med. 1989 Oct; 113(10):1155-8. PMID: 2802945.
      View in: PubMed
    363. Anderson IC, Shpall EJ, Leslie DS, Nustad K, Ugelstad J, Peters WP, Bast RC. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res. 1989 Aug 15; 49(16):4659-64. PMID: 2663144.
      View in: PubMed
    364. Boyer CM, Dawson DV, Neal SE, Winchell LF, Leslie DS, Ring D, Bast RC. Differential induction by interferons of major histocompatibility complex-encoded and non-major histocompatibility complex-encoded antigens in human breast and ovarian carcinoma cell lines. Cancer Res. 1989 Jun 01; 49(11):2928-34. PMID: 2497969.
      View in: PubMed
    365. Berchuck A, Soisson AP, Clarke-Pearson DL, Soper JT, Boyer CM, Kinney RB, McCarty KS, Bast RC. Immunohistochemical expression of CA 125 in endometrial adenocarcinoma: correlation of antigen expression with metastatic potential. Cancer Res. 1989 Apr 15; 49(8):2091-5. PMID: 2702650.
      View in: PubMed
    366. Ramakrishnan S, Xu FJ, Brandt SJ, Niedel JE, Bast RC, Brown EL. Constitutive production of macrophage colony-stimulating factor by human ovarian and breast cancer cell lines. J Clin Invest. 1989 Mar; 83(3):921-6. PMID: 2646321.
      View in: PubMed
    367. Ciobanu N, Runowicz CD, Wiernik PH, Strauman T, Sheridan C, Bast RC. CA 125 levels in patients with ovarian carcinoma undergoing autologous bone marrow transplantation. Am J Obstet Gynecol. 1989 Feb; 160(2):354-5. PMID: 2644834.
      View in: PubMed
    368. Boyer CM, Borowitz MJ, McCarty KS, Kinney RB, Everitt L, Dawson DV, Ring D, Bast RC. Heterogeneity of antigen expression in benign and malignant breast and ovarian epithelial cells. Int J Cancer. 1989 Jan 15; 43(1):55-60. PMID: 2463226.
      View in: PubMed
    369. Jacobs I, Bast RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan; 4(1):1-12. PMID: 2651469.
      View in: PubMed
    370. Peters WP, Stuart A, Klotman M, Gilbert C, Jones RB, Shpall EJ, Gockerman J, Bast RC, Moore JO. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study. Cancer Chemother Pharmacol. 1989; 23(6):377-83. PMID: 2653660.
      View in: PubMed
    371. Bast RC. Antigens associated with epithelial ovarian carcinomas. Prog Clin Biol Res. 1989; 288:73-83. PMID: 2785696.
      View in: PubMed
    372. Zalutsky MR, Bast RC, Knapp RC. Pharmacokinetics of a radioiodinated monoclonal antibody F(ab')2 fragment in a xenograft model with circulating antigen. Int J Rad Appl Instrum B. 1989; 16(4):405-11. PMID: 2777582.
      View in: PubMed
    373. Einhorn N, Knapp RC, Bast RC, Zurawski VR. CA 125 assay used in conjunction with CA 15-3 and TAG-72 assays for discrimination between malignant and non-malignant diseases of the ovary. Acta Oncol. 1989; 28(5):655-7. PMID: 2590540.
      View in: PubMed
    374. Conkling PR, Chua CC, Nadler P, Greenberg CS, Doty E, Misukonis MA, Haney AF, Bast RC, Weinberg JB. Clinical trials with human tumor necrosis factor: in vivo and in vitro effects on human mononuclear phagocyte function. Cancer Res. 1988 Oct 01; 48(19):5604-9. PMID: 3046744.
      View in: PubMed
    375. Peters WP, Shpall EJ, Jones RB, Olsen GA, Bast RC, Gockerman JP, Moore JO. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988 Sep; 6(9):1368-76. PMID: 3047332.
      View in: PubMed
    376. Malkasian GD, Knapp RC, Lavin PT, Zurawski VR, Podratz KC, Stanhope CR, Mortel R, Berek JS, Bast RC, Ritts RE. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988 Aug; 159(2):341-6. PMID: 2457318.
      View in: PubMed
    377. Olsen GA, Gockerman JP, Bast RC, Borowitz M, Peters WP. Altered immunologic reconstitution after standard-dose chemotherapy or high-dose chemotherapy with autologous bone marrow support. Transplantation. 1988 Jul; 46(1):57-60. PMID: 3293287.
      View in: PubMed
    378. Zurawski VR, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, Bast RC, Ritts RE, Malkasian G. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988 May; 30(1):7-14. PMID: 2452773.
      View in: PubMed
    379. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, Shpall EJ, Bast RC, Gilbert CJ, Oette DH. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988 Apr 07; 318(14):869-76. PMID: 3281007.
      View in: PubMed
    380. Knauf S, Bast RC. Tumor antigen NB/70K and CA 125 levels in the blood of preoperative ovarian cancer patients and controls: a preliminary report of the use of the NB12123 and CA 125 radioimmunoassays alone and in combination. Int J Biol Markers. 1988 Apr-Jun; 3(2):75-81. PMID: 3243980.
      View in: PubMed
    381. Lidor Y, Bast RC. Serotherapy of ovarian cancer. Nat Immun Cell Growth Regul. 1988; 7(4):193-215. PMID: 3070370.
      View in: PubMed
    382. Zalutsky MR, Knapp RC, Bast RC. Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. Int J Rad Appl Instrum B. 1988; 15(4):431-7. PMID: 3255739.
      View in: PubMed
    383. Koerner TJ, Hamilton TA, Introna M, Tannenbaum CS, Bast RC, Adams DO. The early competence genes JE and KC are differentially regulated in murine peritoneal macrophages in response to lipopolysaccharide. Biochem Biophys Res Commun. 1987 Dec 31; 149(3):969-74. PMID: 3426621.
      View in: PubMed
    384. Peters WP, Henner WD, Grochow LB, Olsen G, Edwards S, Stanbuck H, Stuart A, Gockerman J, Moore J, Bast RC, et al. Clinical and pharmacologic effects of high dose single agent busulfan with autologous bone marrow support in the treatment of solid tumors. Cancer Res. 1987 Dec 01; 47(23):6402-6. PMID: 2824032.
      View in: PubMed
    385. Leoni F, Bast RC, Canevari S, Menard S, Soper JT, Colnaghi MI. Immunochemical characterization and radioimmunometric detection of molecules shed by human ovarian cancer. Int J Cancer. 1987 Nov 15; 40(5):592-7. PMID: 2445699.
      View in: PubMed
    386. Bast RC, Hunter V, Knapp RC. Pros and cons of gynecologic tumor markers. Cancer. 1987 Oct 15; 60(8 Suppl):1984-92. PMID: 2443235.
      View in: PubMed
    387. Haleem A, Kurtzberg J, Olsen GA, Rhinehardt-Clark A, Leslie DS, Ray L, Smith CA, Peters WP, Haynes BF, Bast RC. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement. Cancer Res. 1987 Sep 01; 47(17):4608-12. PMID: 3113721.
      View in: PubMed
    388. Introna M, Bast RC, Tannenbaum CS, Hamilton TA, Adams DO. The effect of LPS on expression of the early "competence" genes JE and KC in murine peritoneal macrophages. J Immunol. 1987 Jun 01; 138(11):3891-6. PMID: 3108379.
      View in: PubMed
    389. Zurawski VR, Broderick SF, Pickens P, Knapp RC, Bast RC. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol. 1987 Apr; 69(4):606-11. PMID: 2434895.
      View in: PubMed
    390. Introna M, Bast RC, Johnston PA, Adams DO, Hamilton TA. Homologous and heterologous desensitization of proto-oncogene cfos expression in murine peritoneal macrophages. J Cell Physiol. 1987 Apr; 131(1):36-42. PMID: 3571335.
      View in: PubMed
    391. Lavin PT, Knapp RC, Malkasian G, Whitney CW, Berek JC, Bast RC. CA 125 for the monitoring of ovarian carcinoma during primary therapy. Obstet Gynecol. 1987 Feb; 69(2):223-7. PMID: 2433652.
      View in: PubMed
    392. Lan MS, Bast RC, Colnaghi MI, Knapp RC, Colcher D, Schlom J, Metzgar RS. Co-expression of human cancer-associated epitopes on mucin molecules. Int J Cancer. 1987 Jan 15; 39(1):68-72. PMID: 2432019.
      View in: PubMed
    393. Bast RC, Knapp RC. The emerging role of monoclonal antibodies in the clinical management of epithelial ovarian carcinoma. Important Adv Oncol. 1987; 39-53. PMID: 3331386.
      View in: PubMed
    394. Davis HM, Zurawski VR, Bast RC, Klug TL. Characterization of the CA 125 antigen associated with human epithelial ovarian carcinomas. Cancer Res. 1986 Dec; 46(12 Pt 1):6143-8. PMID: 2430690.
      View in: PubMed
    395. Introna M, Hamilton TA, Kaufman RE, Adams DO, Bast RC. Treatment of murine peritoneal macrophages with bacterial lipopolysaccharide alters expression of c-fos and c-myc oncogenes. J Immunol. 1986 Oct 15; 137(8):2711-5. PMID: 3760571.
      View in: PubMed
    396. Eder JP, Bast RC, Peters WP, Henner D, Sanchez E, Schryber S, Frei E, Schnipper LE. Prediction of the optimal timing of bone marrow reinfusion after high dose chemotherapy. Cancer Res. 1986 Sep; 46(9):4496-9. PMID: 3524814.
      View in: PubMed
    397. Niloff JM, Knapp RC, Lavin PT, Malkasian GD, Berek JS, Mortel R, Whitney C, Zurawski VR, Bast RC. The CA 125 assay as a predictor of clinical recurrence in epithelial ovarian cancer. Am J Obstet Gynecol. 1986 Jul; 155(1):56-60. PMID: 3460341.
      View in: PubMed
    398. Barbieri RL, Niloff JM, Bast RC, Scaetzl E, Kistner RW, Knapp RC. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril. 1986 May; 45(5):630-4. PMID: 3457709.
      View in: PubMed
    399. Peters WP, Eder JP, Henner WD, Schryber S, Wilmore D, Finberg R, Schoenfeld D, Bast R, Gargone B, Antman K, et al. High-dose combination alkylating agents with autologous bone marrow support: a Phase 1 trial. J Clin Oncol. 1986 May; 4(5):646-54. PMID: 3517240.
      View in: PubMed
    400. Berek JS, Knapp RC, Malkasian GD, Lavin PT, Whitney C, Niloff JM, Bast RC. CA 125 serum levels correlated with second-look operations among ovarian cancer patients. Obstet Gynecol. 1986 May; 67(5):685-9. PMID: 3457330.
      View in: PubMed
    401. Einhorn N, Bast RC, Knapp RC, Tjernberg B, Zurawski VR. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol. 1986 Mar; 67(3):414-6. PMID: 2418395.
      View in: PubMed
    402. Bregni M, De Fabritiis P, Raso V, Greenberger J, Lipton J, Nadler L, Rothstein L, Ritz J, Bast RC. Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates. Cancer Res. 1986 Mar; 46(3):1208-13. PMID: 3510720.
      View in: PubMed
    403. Greenberger JS, FitzGerald TJ, Rothstein L, Pierce J, Sakakeeny MA, Weichselbaum RR, Naparstek E, Newburger P, Griffin J, Bast R, et al. Long-term culture of human granulocytes and granulocyte progenitor cells. Prog Clin Biol Res. 1986; 211:159-85. PMID: 3008194.
      View in: PubMed
    404. De Fabritiis P, Bregni M, Lipton J, Reynolds C, Nadler L, Ritz J, Bast RC. Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leuk Res. 1986; 10(1):35-42. PMID: 2935682.
      View in: PubMed
    405. Sekine H, Hayes DF, Ohno T, Keefe KA, Schaetzl E, Bast RC, Knapp R, Kufe DW. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma. J Clin Oncol. 1985 Oct; 3(10):1355-63. PMID: 2413181.
      View in: PubMed
    406. Mahvi DM, Meyers WC, Bast RC, Seigler HF, Metzgar RS. Carcinoma of the pancreas. Therapeutic efficacy as defined by a serodiagnostic test utilizing a monoclonal antibody. Ann Surg. 1985 Oct; 202(4):440-5. PMID: 4051597.
      View in: PubMed
    407. Bast RC, Siegal FP, Runowicz C, Klug TL, Zurawski VR, Schonholz D, Cohen CJ, Knapp RC. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma. Gynecol Oncol. 1985 Sep; 22(1):115-20. PMID: 2410329.
      View in: PubMed
    408. Berek JS, Knapp RC, Hacker NF, Lichtenstein A, Jung T, Spina C, Obrist R, Griffiths CT, Berkowitz RS, Parker L, et al. Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. Am J Obstet Gynecol. 1985 Aug 15; 152(8):1003-10. PMID: 2992276.
      View in: PubMed
    409. Knauf S, Anderson DJ, Knapp RC, Bast RC. A study of the NB/7OK and CA 125 monoclonal antibody radioimmunoassays for measuring serum antigen levels in ovarian cancer patients. Am J Obstet Gynecol. 1985 Aug 01; 152(7 Pt 1):911-3. PMID: 2411137.
      View in: PubMed
    410. Niloff JM, Knapp RC, Jones G, Schaetzl EM, Bast RC. Recombinant leukocyte alpha interferon in advanced ovarian carcinoma. Cancer Treat Rep. 1985 Jul-Aug; 69(7-8):895-6. PMID: 4016797.
      View in: PubMed
    411. Bast RC, Knapp RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 1985 Jun; 19(6):354-6. PMID: 4018373.
      View in: PubMed
    412. De Fabritiis P, Bregni M, Lipton J, Greenberger J, Nadler L, Rothstein L, Korbling M, Ritz J, Bast RC. Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood. 1985 May; 65(5):1064-70. PMID: 3995166.
      View in: PubMed
    413. Niloff JM, Bast RC, Schaetzl EM, Knapp RC. Predictive value of CA 125 antigen levels in second-look procedures for ovarian cancer. Am J Obstet Gynecol. 1985 Apr 01; 151(7):981-6. PMID: 3157319.
      View in: PubMed
    414. Greenberger JS, Rothstein L, DeFabritiis P, Bregni M, Bast R, Ritz J, Nadler LM, Lipton JM, Sakakeeny MA. Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. Cancer Res. 1985 Feb; 45(2):758-67. PMID: 3967246.
      View in: PubMed
    415. Bast RC, De Fabritiis P, Lipton J, Gelber R, Maver C, Nadler L, Sallan S, Ritz J. Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb; 45(2):499-503. PMID: 3967224.
      View in: PubMed
    416. Obrist R, Obrecht JP, Bast RC, Sandberg AL. Chemotactic anti-tumor antibodies: in vitro results with four different antibody preparations. Adv Exp Med Biol. 1985; 186:827-32. PMID: 4050600.
      View in: PubMed
    417. Berek JS, Bast RC, Lichtenstein A, Hacker NF, Spina CA, Lagasse LD, Knapp RC, Zighelboim J. Lymphocyte cytotoxicity in the peritoneal cavity and blood of patients with ovarian cancer. Obstet Gynecol. 1984 Nov; 64(5):708-14. PMID: 6493663.
      View in: PubMed
    418. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC. CA125 antigen levels in obstetric and gynecologic patients. Obstet Gynecol. 1984 Nov; 64(5):703-7. PMID: 6208522.
      View in: PubMed
    419. Bast RC, Knapp RC. Immunologic approaches to the management of ovarian carcinoma. Semin Oncol. 1984 Sep; 11(3):264-74. PMID: 6207593.
      View in: PubMed
    420. Lichtenstein A, Berek J, Bast R, Spina C, Hacker N, Knapp RC, Zighelboim J. Activation of peritoneal lymphocyte cytotoxicity in patients with ovarian cancer by intraperitoneal treatment with Corynebacterium parvum. J Biol Response Mod. 1984 Aug; 3(4):371-8. PMID: 6541243.
      View in: PubMed
    421. Bast RC, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, Zurawski VR, Knapp RC. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984 Jul 01; 149(5):553-9. PMID: 6204531.
      View in: PubMed
    422. Masuho Y, Zalutsky M, Knapp RC, Bast RC. Interaction of monoclonal antibodies with cell surface antigens of human ovarian carcinomas. Cancer Res. 1984 Jul; 44(7):2813-9. PMID: 6202400.
      View in: PubMed
    423. Niloff JM, Klug TL, Schaetzl E, Zurawski VR, Knapp RC, Bast RC. Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix. Am J Obstet Gynecol. 1984 Apr 15; 148(8):1057-8. PMID: 6201072.
      View in: PubMed
    424. Klug TL, Bast RC, Niloff JM, Knapp RC, Zurawski VR. Monoclonal antibody immunoradiometric assay for an antigenic determinant (CA 125) associated with human epithelial ovarian carcinomas. Cancer Res. 1984 Mar; 44(3):1048-53. PMID: 6198078.
      View in: PubMed
    425. Feig LA, Bast RC, Knapp RC, Cooper GM. Somatic activation of rasK gene in a human ovarian carcinoma. Science. 1984 Feb 17; 223(4637):698-701. PMID: 6695178.
      View in: PubMed
    426. Ritz J, Bast RC, Takvorian T, Sallan SE. Clinical applications of monoclonal antibodies in acute leukemia. Ann N Y Acad Sci. 1984; 428:308-17. PMID: 6234835.
      View in: PubMed
    427. Kabawat SE, Bast RC, Welch WR, Knapp RC, Bhan AK. Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms. Int J Cancer. 1983 Nov 15; 32(5):547-54. PMID: 6358053.
      View in: PubMed
    428. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983 Oct 13; 309(15):883-7. PMID: 6310399.
      View in: PubMed
    429. Berkowitz R, Kabawat S, Lazarus H, Colvin R, Knapp R, Bast RC. Comparison of a rabbit heteroantiserum and a murine monoclonal antibody raised against a human epithelial ovarian carcinoma cell line. Am J Obstet Gynecol. 1983 Jul 15; 146(6):607-12. PMID: 6346879.
      View in: PubMed
    430. Bast RC, Reinherz EL, Maver C, Lavin P, Schlossman SF. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol. 1983 Jul; 28(1):101-14. PMID: 6409485.
      View in: PubMed
    431. Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum. Cancer Res. 1983 Mar; 43(3):1395-401. PMID: 6825108.
      View in: PubMed
    432. Bast RC, Ritz J, Lipton JM, Feeney M, Sallan SE, Nathan DG, Schlossman SF. Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res. 1983 Mar; 43(3):1389-94. PMID: 6337707.
      View in: PubMed
    433. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB. Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983; 2(3):275-85. PMID: 6196309.
      View in: PubMed
    434. Ritz J, Sallan SE, Bast RC, Lipton JM, Nathan DG, Schlossman SF. In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. Haematol Blood Transfus. 1983; 28:117-23. PMID: 6345287.
      View in: PubMed
    435. Obrist R, Reilly R, Leavitt T, Knapp RC, Bast RC. Monocyte chemotaxis mediated by formyl-methionyl-leucyl-phenylalanine conjugated with monoclonal antibodies against human ovarian carcinoma. Int J Immunopharmacol. 1983; 5(4):307-14. PMID: 6629591.
      View in: PubMed
    436. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB. Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol. 1983 Jan; 79(1):98-104. PMID: 6336888.
      View in: PubMed
    437. Valone FH, Obrist R, Tarlin N, Bast RC. Enhanced arachidonic acid lipoxygenation by K562 cells stimulated with 12-O-tetradecanoylphorbol-13-acetate. Cancer Res. 1983 Jan; 43(1):197-201. PMID: 6401164.
      View in: PubMed
    438. Galli SJ, Bast RC, Bast BS, Isomura T, Zbar B, Rapp HJ, Dvorak HF. Bystander suppression of tumor growth: evidence that specific targets and bystanders are damaged by injury to a common microvasculature. J Immunol. 1982 Aug; 129(2):890-9. PMID: 6282973.
      View in: PubMed
    439. Bast RC, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov; 68(5):1331-7. PMID: 7028788.
      View in: PubMed
    440. Feeney M, Knapp RC, Greenberger JS, Bast RC. Elimination of leukemic cells from rat bone marrow using antibody and complement. Cancer Res. 1981 Sep; 41(9 Pt 1):3331-5. PMID: 6942913.
      View in: PubMed
    441. Bast RC, Miller H, Rapp HJ, Gelboin HV. Aryl hydrocarbon (benzo[a]pyrene) hydroxylase in guinea pig lymphoid tissue. J Natl Cancer Inst. 1981 Aug; 67(2):359-64. PMID: 6943374.
      View in: PubMed
    442. Clavell LA, Lipton JM, Bast RC, Kudisch M, Pesando J, Scholssman SF, Ritz J. Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood. 1981 Aug; 58(2):333-6. PMID: 6941821.
      View in: PubMed
    443. Berkowitz RS, Hornig-Rohan J, Martin-Alosco S, Klein S, Goldstein DP, Bast RC, DeWolf WC. HL-A antigen frequency distribution in patients with gestational choriocarcinoma and their husbands. Placenta Suppl. 1981; 3:263-7. PMID: 6963960.
      View in: PubMed
    444. Frei E, Blum RH, Pitman SW, Kirkwood JM, Henderson IC, Skarin AT, Mayer RJ, Bast RC, Garnick MB, Parker LM, Canellos GP. High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med. 1980 Mar; 68(3):370-6. PMID: 6965819.
      View in: PubMed
    445. Bast RC, Knapp RC, Donahue VC, Thurston JG, Mitchell AK, Feeney M, Schlossman SF. Specificity of heteroantisera developed against purified populations of intact murine ovarian carcinoma cells. J Natl Cancer Inst. 1980 Feb; 64(2):365-72. PMID: 6986493.
      View in: PubMed
    446. Bast RC, Knapp RC, Mitchell AK, Thurston JG, Tucker RW, Schlossman SF. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity. J Immunol. 1979 Nov; 123(5):1945-51. PMID: 489967.
      View in: PubMed
    447. Okuda T, Vesell ES, Plotkin E, Tarone R, Bast RC, Gelboin HV. Interindividual and intraindividual variations in aryl hydrocarbon hydroxylase in monocytes from monozygotic and dizygotic twins. Cancer Res. 1977 Nov; 37(11):3904-11. PMID: 561657.
      View in: PubMed
    448. Okuda T, Bast RC, Miller H, Rapp HJ, Gelboin HV. The half-life of aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human blood monocytes. Chem Biol Interact. 1976 Aug; 14(3-4):379-82. PMID: 954153.
      View in: PubMed
    449. Bast RC, Okuda T, Plotkin E, Tarone R, Rapp HJ, Gelboin HV. Development of an assay for aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Cancer Res. 1976 Jun; 36(6):1967-74. PMID: 1268850.
      View in: PubMed
    450. Detrick-Hooks B, Smith HG, Bast RC, Dunkel VC, Borsos T. Naturally soluble tumor antigens from guinea pig hepatomas: isolation and partial characterization. J Immunol. 1976 May; 116(5):1324-31. PMID: 178795.
      View in: PubMed
    451. Bast RC, Segerling M, Ohanian SH, Greene SL, Zbar B, Rapp HJ, Borsos T. Regression of established tumors and induction of tumor immunity by intratumor chemotherapy. J Natl Cancer Inst. 1976 Apr; 56(4):829-32. PMID: 176411.
      View in: PubMed
    452. Borsos T, Bast RC, Ohanian SH, Segerling M, Zbar B, Rapp HJ. Induction of tumor immunity by intratumoral chemotherapy. Ann N Y Acad Sci. 1976; 276:565-72. PMID: 194520.
      View in: PubMed
    453. Bast RC, Bast BS. Critical review of previously reported animal studies of tumor immunotherapy with nonspecific immunostimulants. Ann N Y Acad Sci. 1976; 277(00):60-93. PMID: 826208.
      View in: PubMed
    454. Smith HG, Bast RC, Zbar B, Rapp HJ. Eradication of microscopic lymph nodes metastases after injection of living BCG adjacent to the primary tumor. J Natl Cancer Inst. 1975 Dec; 55(6):1345-52. PMID: 1107574.
      View in: PubMed
    455. Bast RC, Zbar B, Rapp HJ. Local antitumor activity of a primary and an anamnestic response to a syngeneic guinea pig hepatoma. J Natl Cancer Inst. 1975 Oct; 55(4):989-94. PMID: 171435.
      View in: PubMed
    456. Bast RC, Zbar B, Mackaness GB, Rapp HJ. Antitumor activity of bacterial infection. I. Effect of Listeria monocytogenes on growth of a murine fibrosarcoma. J Natl Cancer Inst. 1975 Mar; 54(3):749-56. PMID: 804566.
      View in: PubMed
    457. Bast RC, Zbar B, Miller TE, Mackaness GB, Rapp HJ. Antitumor activity of bacterial infection. II. effect of Listeria monocytogenes on growth of a guinea pig hepatoma. J Natl Cancer Inst. 1975 Mar; 54(3):757-61. PMID: 164568.
      View in: PubMed
    458. Bast RC, Doos WG, Zbar B, Harmel RP, Dalgard DW, Steward AM. Intracolonic injection of BCG in the rhesus monkey. J Natl Cancer Inst. 1974 Nov; 53(5):1423-6. PMID: 4431061.
      View in: PubMed
    459. Bast RC, Whitlock JP, Miller H, Rapp HJ, Gelboin HV. Aryl hydrocarbon (benzo(a)pyrene) hydroxylase in human peripheral blood monocytes. Nature. 1974 Aug 23; 250(5468):664-5. PMID: 4850643.
      View in: PubMed
    460. Dunkel VC, Bast RC, Gerwin BI, Heine U, Cottler-Fox M, Borsos T. Presence of A-type and absence of C-type virus particles in a chemically induced guinea pig hepatoma. J Natl Cancer Inst. 1974 Aug; 53(2):591-3. PMID: 4135601.
      View in: PubMed
    461. Zwilling BS, Leonard EJ, Bast RC, Zbar B. Destruction of syngeneic tumors by tuberculin-stimulated peritoneal exudate cells from guinea pigs immunized to Mycobacterium bovis (strain BCG). J Natl Cancer Inst. 1974 Aug; 53(2):541-6. PMID: 4367248.
      View in: PubMed
    462. Bast RC, Zbar B, Borsos T, Rapp HJ. BCG and cancer. N Engl J Med. 1974 Jun 27; 290(26):1458-69. PMID: 4598691.
      View in: PubMed
    463. Bast RC, Zbar B, Borsos T, Rapp HJ. BCG and cancer (first of two parts). N Engl J Med. 1974 Jun 20; 290(25):1413-20. PMID: 4364286.
      View in: PubMed
    464. Bast RC, Cleveland RP, Littman BH, Zbar B, Rapp HJ. Acquired cellular immunity: extracellular killing of Listeria monocytogenes by a product of immunologically activated macrophages. Cell Immunol. 1974 Feb; 10(2):248-59. PMID: 4218128.
      View in: PubMed
    465. Bast RC, Shears BW, Rapp HJ, Gelboin HV. Aryl hydrocarbon (benzo(alpha)pyrene) hydroxylase in guinea pig peritoneal macrophages: benz(alpha)anthracene-induced increase of enzyme activity in vivo and in cell culture. J Natl Cancer Inst. 1973 Aug; 51(2):675-8. PMID: 4765380.
      View in: PubMed
    466. Dvorak AM, Bast RC, Dvorak HF. Morphologic changes in draining lymph nodes and in lymphocyte cultures after sensitization with complete or incomplete Freund's adjuvant. Correlation with immunologic events in vivo and in culture. J Immunol. 1971 Aug; 107(2):422-35. PMID: 5568772.
      View in: PubMed
    467. Dvorak HF, Simpson BA, Bast RC, Leskowitz S. Cutaneous basophil hypersensitivity. 3. Participation of the basophil in hypersensitivity to antigen-antibody complexes, delayed hypersensitivity and contact allergy. Passive transfer. J Immunol. 1971 Jul; 107(1):138-48. PMID: 5091955.
      View in: PubMed
    468. Bast RC, Simpson BA, Dvorak HF. Heterogeneity of the cellular immune response. II. The role of adjuvant, lymphocyte stimulation in cutaneous basophil hypersensitivity. J Exp Med. 1971 Feb 01; 133(2):202-15. PMID: 5316262.
      View in: PubMed
    469. Bast RC, Manseau EJ, Dvorak HF. Heterogeneity of the cellular immune response. I. Kinetics of lymphocyte stimulation during sensitization and recovery from tolerance. J Exp Med. 1971 Feb 01; 133(2):187-201. PMID: 5316261.
      View in: PubMed
    470. Dvorak HF, Bast RC. Nature of the immunogen in crystalline serum albumins. Immunochemistry. 1970 Jan; 7(1):118-24. PMID: 5416390.
      View in: PubMed
    471. Dvorak HF, Simpson BA, Bast RC. Immunologic unresponsiveness in the adult guinea pig. IV. Induction of unresponsiveness with aggregated serum proteins. J Immunol. 1969 May; 102(5):1163-71. PMID: 4181547.
      View in: PubMed
    472. Heilman DH, Bast RC. In vitro assay of endotoxin by the inhibition of macrophage migration. J Bacteriol. 1967 Jan; 93(1):15-20. PMID: 5335889.
      View in: PubMed
    473. Serum proteomics yield new biomarkers for ovarian cancer. Cancer Biology and Therapy. 3:794-795.
    474. Using tumor markers in cancer screening and follow-up. Patient Care. 33:109-124.
    475. Development of a new sensitive immunoradiometric assay for CA125. Journal of Tumor Marker Oncology. 3:65-71.
    476. Characterization of the ARHI tumor-suppressor as a target for gene therapy in ovarian cancer. Geburtshilfe und Frauenheilkunde. 62:870-876.
    477. Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche. Cancer Cell.
    478. International Journal of Radiation Applications and Instrumentation. 16:405-411.
    479. A review of intraperitoneal therapy of human ovarian carcinoma. Peritoneal Dialysis Bulletin. 3:59-62.
    480. PROCEEDINGS, XI INTERNATIONAL CANCER CONGRESS, FLORENCE 1974. 333-336.
    481. Clinically relevant microRNAs in ovarian cancer. Molecular Cancer Research. 13:393-401.
    482. Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer. 16.
    483. New approach to serotherapy of human ovarian carcinoma. Gynecologic Oncology. 10:370.
    484. ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death and Disease. 6.
    485. Serum 125Ca levels correlated with survival in epithelial ovarian cancer. 470-472.
    486. Intraperitoneal immunotherapy of human ovarian carcinoma with corynebacterium parvum.
    487. The emerging role of HE4 in the evaluation of epithelial Ovarian and endometrial carcinomas. ONCOLOGY (United States). 27.
    488. Reply to Davies et al. American Journal of Obstetrics and Gynecology. 151:420.
    489. Application of artificial neural networks in ovarian cancer early detection. 107-112.
    490. Advances in the detection of marrow micrometastases in breast cancer. Cancer Research Therapy and Control. 4:43-47.
    491. Monitoring epithelial ovarian cancer. Laboratory Medicine. 16:315-318.
    492. CA 125 and polymorphic epithelial mucin as serum tumor markers. Cancer Reviews. 11-12:119-144.
    493. Tumor necrosis factor-α and Interferon-γ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget. 7:14871-14884.
    494. Gankyrin facilitates follicle-stimulating hormone-driven ovarian cancer cell proliferation through the PI3K/AKT/HIF-1α/cyclin D1 pathway. Oncogene.
    495. Immunotherapy with BCG. 35-40.
    496. Detection and partial purification of a 30 kDa ovarian carcinoma-associated protein. Cancer Molecular Biology. 3:915-926.
    497. Validation of a novel biomarker panel for the detection of ovarian cancer. Cancer Epidemiology Biomarkers and Prevention. 25:1333-1340.
    498. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer. International Journal of Gynecological Cancer. 26:43-51.
    499. Influence of circulating antigen on blood pool activity of a radioiodinated monoclonal antibody. International Journal of Radiation Applications and Instrumentation. 15:431-437.
    500. Antigenic heterogeneity in human ovarian cancer. Obstetrical and Gynecological Survey. 46:59-61.
    501. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Oncology Practice. 3:336-339.
    502. Erratum. European Journal of Cancer. 40:628.
    503. Targeting therapies in cancer. 167-182.
    504. Molecular Pathogenesis of Ovarian Cancer.
    505. Clinical studies of an oncofetal antigen (DU-PAN-2) detected by a monoclonal antibody to pancreatic adenocarcinoma.
    506. Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Akt-mTOR Inhibition. EBioMedicine. 6:149-161.
    507. Erratum to. Autophagy. 10:1482.
    508. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. International Journal of Gynecological Cancer. 26:1070-1077.
    509. Molecular approaches to management of epithelial ovarian cancer. International Journal of Gynecological Cancer. 10:2-7.
    510. Elevated serum levels of macrophage colony-stimulating factor and OVX1, 11 months prior to the diagnosis of stage IC ovarian cancer. International Journal of Gynecological Cancer. 6:156-158.
    511. Enhanced cytotoxic effects of combined valproic acid and the Aurora kinase inhibitor VE465 on gynecologic cancer cells. Frontiers in Oncology. 3 MAR.
    512. Molecular targets for epithelial ovarian cancer. 606-618.
    513. In reply. Journal of Clinical Oncology. 26:2060-2061.
    514. Current challenges and future directions in the management of ovarian cancer. Clinical Ovarian Cancer. 3:81-97.
    515. Early Detection of Cancer. 335-347.
    516. Conclusions and recommendations from the Helene Harris Memorial Trust Sixth Biennial International Forum on Ovarian Cancer, May 10-14, 1997, Los Angeles, California, USA. International Journal of Gynecological Cancer. 7:416-424.
    517. The Salmonella mutagenesis test (SMT) and CFU-GM assay as a guide for bone marrow re-infusion in the autologous transplantations setting.
    518. Biomarkers of 4-hpr in response of ovarian carcinoma ov-ca 433 cells. Cancer Journal. 9:518.
    519. Ovarian cancer identified through screening with serum markers but not by pelvic imaging. International Journal of Gynecological Cancer. 9:497-501.
    520. Molecular Pathogenesis of Epithelial Ovarian Cancer. 441-454.
    521. NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget. 7:3018-3032.
    522. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. Obstetrical and Gynecological Survey. 39:169-171.
    523. CA 125. McGill Journal of Medicine. 3:67-71.
    524. ENSAYO DEL CA 125 EMPLEADO CONJUNTAMENTE CON LOS ENSAYOS DEL CA 15-3 Y DEL TAG-72 EN LA DISCRIMINACION ENTRE LOS PROCESOS MALIGNOS Y NO MALIGNOS DE OVARIO. Oncologia. 13:273-276.
    525. Correction to Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2 [Molecular Cell 61, 520-534, (2016)]. Molecular Cell. 61:640.
    526. In reply [8]. Journal of Clinical Oncology. 25:1294.
    527. Use of biomarkers to guide decisions on adjuvant systemic therapy forwomenwith early-stage invasive breast cancer. Journal of Clinical Oncology. 34:1134-1150.
    528. Increased arachidonic acid lipoxygenation by phorbol myristat acetate (PMA)-stimulated K562 cells. Clinical Research. 30.
    529. Regulates paclitaxel sensitivity in ovarian cancer cells by modulating AKT ativation, p21Cip1- and p27Kip1-mediated G1 cell cycle arrest and apoptosis. PLoS One. 10.
    530. Epac1 knockdown inhibits the proliferation of ovarian cancer cells by inactivating AKT/Cyclin D1/CDK4 pathway in vitro and in vivo. Medical Oncology. 33.
    531. Rethinking ovarian cancer II. Nature Reviews Cancer. 15:668-679.
    532. Series Foreword. Unknown Journal. 9781118501627:ix-x.
    533. Aryl hydrocarbon hydroxylase in human monocytes. 743.
    534. Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients. EBioMedicine.
    535. Nature of the immunogen in crystalline serum albumins. Immunochemistry. 7.
    536. Intraperitoneale immuntherapie des epithelialen ovarialkarzinoms mit corynebacterium parvam. Gynakologisch-geburtshilfliche Rundschau. 26:222-224.
    537. Tissue distribution and characteristics of the CA 125 antigen. Cancer Reviews. 11-12:102-118.
    538. Molecular Mechanisms of Pathogenesis and Progression of Epithelial Ovarian Cancer. 625-645.
    BAST JR's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description